Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

KEVIN D CANNON

Allopathic & Osteopathic Physicians Hospitalist

NPI
1700897022
CMS profile
122867
Location
WILMINGTON, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$58.19

2 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

Nature of paymentAmountRecords
Education $32.27 1
Food and Beverage $25.92 1

By paying entity

PY2022 · entire year · sorted by reported total

Paying entityAmountRecords
Novo Nordisk Inc $32.27 1
Boehringer Ingelheim Pharmaceuticals, Inc. $25.92 1

Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

KEVIN D CANNON

NPI 1700897022 · CMS profile ID 122867

Allopathic & Osteopathic Physicians / Hospitalist

WILMINGTON, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1700897022?year=2022&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
KEVIN D CANNON, NPI 1700897022, CMS profile ID 122867. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1700897022?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). KEVIN D CANNON, NPI 1700897022, CMS profile ID 122867. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1700897022?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
KEVIN D CANNON, NPI 1700897022, CMS profile ID 122867, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1700897022?year=2022&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

2 matching records · $58.19 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 2 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–2 of 2.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Boehringer Ingelheim Pharmaceuticals, Inc. $25.9208/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 887506015 CMS
Novo Nordisk Inc $32.2706/08/2022 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 898661569 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $3,301.48 16
PY2021 $20.00 1
PY2022 $58.19 2
PY2023 $1,400.30 14
PY2025 $116.03 2

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2021, 2022, 2023, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2021 , PY2022 , PY2023 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $3,200.00 1
PY2025 Principal investigator $6,407,903.58 738
PY2024 Recipient $12,299.41 13
PY2024 Principal investigator $7,058,469.69 390
PY2023 Recipient $3,980.00 2
PY2023 Principal investigator $7,125,617.33 899
PY2022 Recipient $9,082.00 12
PY2022 Principal investigator $6,929,547.49 979
PY2021 Recipient $14,312.20 61
PY2021 Principal investigator $9,361,495.59 2,459
PY2020 Recipient $233.41 1
PY2020 Principal investigator $5,812,787.31 750
PY2019 Principal investigator $4,820,055.08 826

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

826 records in PY2019

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 AstraZeneca Pharmaceuticals LP $1,919.43 12/31/2019 Non-covered Recipient Entity
Pmg Research Of Charlotte Llc
A Long Term Outcomes Study to Assess STatin Residual Risk Reduction with EpaNova in HiGh Cardiovascular Risk PatienTs with Hypertriglyceridemia No dispute reported 06/30/2026 684988691
Principal investigator 1 AstraZeneca UK Limited $798.67 12/31/2019 Non-covered Recipient Entity
Pmg Research Inc
A Long Term Outcomes Study to Assess STatin Residual Risk Reduction with EpaNova in HiGh Cardiovascular Risk PatienTs with Hypertriglyceridemia No dispute reported 06/30/2026 685000957
Principal investigator 1 AstraZeneca UK Limited $1,028.75 12/31/2019 Non-covered Recipient Entity
Pmg Research Of Charlotte Llc
A Long Term Outcomes Study to Assess STatin Residual Risk Reduction with EpaNova in HiGh Cardiovascular Risk PatienTs with Hypertriglyceridemia No dispute reported 06/30/2026 685000993
Principal investigator 1 AstraZeneca UK Limited $943.94 12/31/2019 Non-covered Recipient Entity
Pmg Research Of Hickory
A Long Term Outcomes Study to Assess STatin Residual Risk Reduction with EpaNova in HiGh Cardiovascular Risk PatienTs with Hypertriglyceridemia No dispute reported 06/30/2026 685001019
Principal investigator 1 AstraZeneca UK Limited $1,115.44 12/31/2019 Non-covered Recipient Entity
Pmg Research Of Raleigh
A Long Term Outcomes Study to Assess STatin Residual Risk Reduction with EpaNova in HiGh Cardiovascular Risk PatienTs with Hypertriglyceridemia No dispute reported 06/30/2026 685001053
Principal investigator 1 AstraZeneca UK Limited $713.46 12/31/2019 Non-covered Recipient Entity
Pmg Research Of Wilmington
A Long Term Outcomes Study to Assess STatin Residual Risk Reduction with EpaNova in HiGh Cardiovascular Risk PatienTs with Hypertriglyceridemia No dispute reported 06/30/2026 685001083
Principal investigator 1 Novo Nordisk AS $23.06 12/30/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4506 No dispute reported 06/30/2026 706704183
Principal investigator 1 Novo Nordisk AS $2.99 12/30/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4506 No dispute reported 06/30/2026 706704185
Principal investigator 1 Novo Nordisk AS $23.06 12/27/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4506 No dispute reported 06/30/2026 706703231
Principal investigator 1 Novo Nordisk AS $2.99 12/27/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4506 No dispute reported 06/30/2026 706703233
Principal investigator 1 Novo Nordisk AS $28.33 12/24/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4506 No dispute reported 06/30/2026 706704195
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $10,500.00 12/23/2019 Non-covered Recipient Entity
PMG RESEARCH INC
EFC15294 No dispute reported 06/30/2026 690603609
Principal investigator 1 Novo Nordisk AS $20,664.11 12/23/2019 Non-covered Recipient Entity
PMG RESEARCH INC
EX9536-4388 No dispute reported 06/30/2026 692464189
Principal investigator 1 PFIZER INC. $13,665.12 12/21/2019 Non-covered Recipient Entity
PMG Research of Wilmington LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF 2 DOSES COMPARED TO 3 DOSES OF CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671677953
Principal investigator 1 PFIZER INC. $15,467.23 12/21/2019 Non-covered Recipient Entity
PMG Research of Charlotte
PHASE III LOT CONSISTENCY TRIAL No dispute reported 06/30/2026 671678713
Principal investigator 1 GlaxoSmithKline, LLC. $1,298.70 12/20/2019 Non-covered Recipient Entity
PMG RESEARCH INC
RSV OA=ADJ-002 No dispute reported 06/30/2026 669970011
Principal investigator 1 Novo Nordisk AS $12.99 12/20/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4506 No dispute reported 06/30/2026 706703235
Principal investigator 1 Novo Nordisk AS $12.99 12/20/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4506 No dispute reported 06/30/2026 706703237
Principal investigator 1 Novo Nordisk AS $12.99 12/20/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4506 No dispute reported 06/30/2026 706703239
Principal investigator 1 Novo Nordisk AS $12.99 12/20/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4506 No dispute reported 06/30/2026 706703241
Principal investigator 1 Novo Nordisk AS $12.99 12/20/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4506 No dispute reported 06/30/2026 706703243
Principal investigator 1 Novo Nordisk AS $12.99 12/20/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4506 No dispute reported 06/30/2026 706703245
Principal investigator 1 Novo Nordisk AS $12.99 12/20/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4506 No dispute reported 06/30/2026 706703247
Principal investigator 1 Novo Nordisk AS $12.99 12/20/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4506 No dispute reported 06/30/2026 706703249
Principal investigator 1 Novo Nordisk AS $12.99 12/20/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4506 No dispute reported 06/30/2026 706703251
Principal investigator 1 Novo Nordisk AS $12.99 12/20/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4506 No dispute reported 06/30/2026 706703253
Principal investigator 1 Novo Nordisk AS $12.99 12/20/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4506 No dispute reported 06/30/2026 706703255
Principal investigator 1 Novo Nordisk AS $2,871.68 12/19/2019 Non-covered Recipient Entity
PMG RESEARCH INC
NN9535-4506 No dispute reported 06/30/2026 692464045
Principal investigator 1 Novo Nordisk AS $421.90 12/19/2019 Non-covered Recipient Entity
PMG RESEARCH INC
NN9535-4506 No dispute reported 06/30/2026 692464047
Principal investigator 1 Novo Nordisk AS $3,416.29 12/19/2019 Non-covered Recipient Entity
PMG RESEARCH INC
EX9924-4473 No dispute reported 06/30/2026 692464175
Principal investigator 1 Novo Nordisk AS $27,745.74 12/19/2019 Non-covered Recipient Entity
PMG RESEARCH INC
NN9536-4576 No dispute reported 06/30/2026 692464179
Principal investigator 1 Novo Nordisk AS $16,805.20 12/19/2019 Non-covered Recipient Entity
PMG RESEARCH INC
NN9536-4373 No dispute reported 06/30/2026 692464183
Principal investigator 1 Novo Nordisk AS $1,500.00 12/19/2019 Non-covered Recipient Entity
PMG RESEARCH INC
EX9536-4388 No dispute reported 06/30/2026 692464187
Principal investigator 1 Novo Nordisk AS $8,688.67 12/19/2019 Non-covered Recipient Entity
PMG RESEARCH INC
NN9536-4374 No dispute reported 06/30/2026 692464193
Principal investigator 1 Novo Nordisk AS $12,276.82 12/19/2019 Non-covered Recipient Entity
PMG RESEARCH INC
NN9536-4375 No dispute reported 06/30/2026 692464197
Principal investigator 1 Novo Nordisk AS $24.99 12/19/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 706703257
Principal investigator 1 Novo Nordisk AS $23.06 12/18/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4506 No dispute reported 06/30/2026 706703261
Principal investigator 1 Novo Nordisk AS $9.99 12/18/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4506 No dispute reported 06/30/2026 706703263
Principal investigator 1 SANOFI US SERVICES INC. $4,956.50 12/18/2019 Non-covered Recipient Entity
Pmg Research,Incorporation
A 56-week, Multicenter, Double-blind, Placebo-controlled, Randomized Study to Evaluate the Efficacy and Safety of Efpeglenatide Once Weekly in Patients with Type 2 Diabetes Mellitus Inadequately Contr No dispute reported 06/30/2026 691601993
Principal investigator 1 Merck Sharp & Dohme Corporation $8,918.00 12/16/2019 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691502117
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,722.14 12/12/2019 Non-covered Recipient Entity
PMG RESEARCH INC
A Phase 1, Multicenter, Randomized, Open-Label, Parallel-Group, Multi-Dose Study in Patients With Moderate-to-Severe Pain Due to Osteoarthritis of the Knee or Hip to Assess the Patients' Ability to Self-Administer Fasinumab Using an Auto-Injector and to Characterize the Pharmacokinetics of Fasinumab Using Two Different Presentations No dispute reported 06/30/2026 639750099
Principal investigator 1 GlaxoSmithKline, LLC. $1,898.10 12/11/2019 Non-covered Recipient Entity
PMG RESEARCH INC
RSV OA=ADJ-002 No dispute reported 06/30/2026 669975999
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $79.20 12/10/2019 Non-covered Recipient Entity
Pmg Research Of Wilmington
Phase II study of BI456906 in Patients with T2DM O No dispute reported 06/30/2026 704145839
Principal investigator 1 SANOFI US SERVICES INC. $6,809.75 12/06/2019 Non-covered Recipient Entity
Pmg Research,Incorporation
A 56-week, Multicenter, Double-blind, Placebo-controlled, Randomized Study to Evaluate the Efficacy and Safety of Efpeglenatide Once Weekly in Patients with Type 2 Diabetes Mellitus Inadequately Contr No dispute reported 06/30/2026 691601999
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $32,493.00 12/05/2019 Non-covered Recipient Entity
PMG RESEARCH INC
EFC14868 No dispute reported 06/30/2026 690603603
Principal investigator 1 Novo Nordisk AS $3,950.22 12/05/2019 Non-covered Recipient Entity
PMG RESEARCH INC
NN9535-4506 No dispute reported 06/30/2026 692464041
Principal investigator 1 Novo Nordisk AS $2,078.10 12/05/2019 Non-covered Recipient Entity
PMG RESEARCH INC
NN9535-4506 No dispute reported 06/30/2026 692464043
Principal investigator 1 PFIZER INC. $62,933.51 12/05/2019 Non-covered Recipient Entity
PMG Research of Wilmington LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF 2 DOSES COMPARED TO 3 DOSES OF CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671675767
Principal investigator 1 PFIZER INC. $3,270.40 12/05/2019 Non-covered Recipient Entity
PMG Research of Wilmington LLC
A PHASE 3 RANDOMIZED OPENLABEL TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS 65 YEARS OF AGE WITH PRIOR PNEUMOCOCCAL VACCINATION No dispute reported 06/30/2026 671680025
Principal investigator 1 PFIZER INC. $9,484.16 12/05/2019 Non-covered Recipient Entity
PMG Research of Wilmington LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINENAIVE ADULTS 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671684049
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,785.23 12/05/2019 Non-covered Recipient Entity
PMG RESEARCH INC
PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO AND NSAID CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP No dispute reported 06/30/2026 639750097
Principal investigator 1 SANOFI US SERVICES INC. $675.00 12/05/2019 Non-covered Recipient Entity
Pmg Research,Incorporation
A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin in Patients With Type 2 Diabetes Who Have Inadequate Glyc No dispute reported 06/30/2026 691610507
Principal investigator 1 SANOFI US SERVICES INC. $32,493.00 12/05/2019 Non-covered Recipient Entity
Pmg Research,Incorporation
A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin in Patients With Type 2 Diabetes Who Have Inadequate Glyc No dispute reported 06/30/2026 691610512
Principal investigator 1 GlaxoSmithKline, LLC. $6,353.10 12/04/2019 Non-covered Recipient Entity
PMG RESEARCH INC
RSV OA=ADJ-002 No dispute reported 06/30/2026 669967377
Principal investigator 1 GlaxoSmithKline, LLC. $200.00 12/04/2019 Non-covered Recipient Entity
PMG RESEARCH INC
RSV OA=ADJ-002 No dispute reported 06/30/2026 669967599
Principal investigator 1 GlaxoSmithKline, LLC. $2,500.00 12/04/2019 Non-covered Recipient Entity
PMG RESEARCH INC
RSV OA=ADJ-002 No dispute reported 06/30/2026 669967689
Principal investigator 1 GlaxoSmithKline, LLC. $1,198.80 12/04/2019 Non-covered Recipient Entity
PMG RESEARCH INC
RSV OA=ADJ-002 No dispute reported 06/30/2026 669968089
Principal investigator 1 GlaxoSmithKline, LLC. $4,134.60 12/04/2019 Non-covered Recipient Entity
PMG RESEARCH INC
RSV OA=ADJ-002 No dispute reported 06/30/2026 669974623
Principal investigator 1 PFIZER INC. $5,655.78 12/04/2019 Non-covered Recipient Entity
PMG Research of Hickory LLC
A PHASE 12 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING FIRSTINHUMAN STUDY TO DESCRIBE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A RESPIRATORY SYNCYTIAL VIRUS RSV VACCINE IN HEALTHY ADULTS No dispute reported 06/30/2026 671678487
Principal investigator 1 Novo Nordisk AS $8,328.55 12/03/2019 Non-covered Recipient Entity
PMG RESEARCH INC
EX9924-4473 No dispute reported 06/30/2026 692464173
Principal investigator 1 Novo Nordisk AS $31,866.65 12/03/2019 Non-covered Recipient Entity
PMG RESEARCH INC
NN9536-4576 No dispute reported 06/30/2026 692464177
Principal investigator 1 Novo Nordisk AS $29,265.99 12/03/2019 Non-covered Recipient Entity
PMG RESEARCH INC
NN9536-4373 No dispute reported 06/30/2026 692464181
Principal investigator 1 Novo Nordisk AS $11,853.06 12/03/2019 Non-covered Recipient Entity
PMG RESEARCH INC
EX9536-4388 No dispute reported 06/30/2026 692464185
Principal investigator 1 Novo Nordisk AS $10,610.93 12/03/2019 Non-covered Recipient Entity
PMG RESEARCH INC
NN9536-4374 No dispute reported 06/30/2026 692464191
Principal investigator 1 Novo Nordisk AS $13,578.09 12/03/2019 Non-covered Recipient Entity
PMG RESEARCH INC
NN9536-4375 No dispute reported 06/30/2026 692464195
Principal investigator 1 PFIZER INC. $532.24 11/28/2019 Non-covered Recipient Entity
PMG RESEARCH INC
A PHASE 2 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF TWO 3DOSE REGIMENS OF A CLOSTRIDIUM DIFFICILE VACCINE IN HEALTHY ADULTS AGED 65 TO 85 YEARS No dispute reported 06/30/2026 671669019
Principal investigator 1 PFIZER INC. $3,672.00 11/28/2019 Non-covered Recipient Entity
PMG RESEARCH INC
A PHASE 2 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF TWO 3DOSE REGIMENS OF A CLOSTRIDIUM DIFFICILE VACCINE IN HEALTHY ADULTS AGED 65 TO 85 YEARS No dispute reported 06/30/2026 671670047
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $7,636.52 11/28/2019 Non-covered Recipient Entity
PMG RESEARCH INC
PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO AND NSAID CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP No dispute reported 06/30/2026 639750095
Principal investigator 1 GlaxoSmithKline, LLC. $1,198.80 11/26/2019 Non-covered Recipient Entity
PMG RESEARCH INC
RSV OA=ADJ-002 No dispute reported 06/30/2026 669967597
Principal investigator 1 PFIZER INC. $32,283.72 11/23/2019 Non-covered Recipient Entity
PMG Research of Wilmington LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF 2 DOSES COMPARED TO 3 DOSES OF CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671674269
Principal investigator 1 PFIZER INC. $250.00 11/23/2019 Non-covered Recipient Entity
PMG Research of Wilmington LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF 3 LOTS OF 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINENAIVE ADULTS 18 THROUGH 49 YEARS OF AGE No dispute reported 06/30/2026 671683907
Principal investigator 1 PFIZER INC. $1,244.03 11/22/2019 Non-covered Recipient Entity
PMG Research of Wilmington LLC
A PHASE 3 RANDOMIZED OPENLABEL TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS 65 YEARS OF AGE WITH PRIOR PNEUMOCOCCAL VACCINATION No dispute reported 06/30/2026 671679671
Principal investigator 1 PFIZER INC. $3,988.61 11/22/2019 Non-covered Recipient Entity
PMG Research of Wilmington LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINENAIVE ADULTS 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671682991
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $3,843.00 11/21/2019 Non-covered Recipient Entity
PMG RESEARCH INC
EFC15294 No dispute reported 06/30/2026 690603601
Principal investigator 1 Novo Nordisk AS $3.25 11/21/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4506 No dispute reported 06/30/2026 706703779
Principal investigator 1 Novo Nordisk AS $72.00 11/21/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4506 No dispute reported 06/30/2026 706703781
Principal investigator 1 Novo Nordisk AS $5.30 11/21/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4506 No dispute reported 06/30/2026 706703783
Principal investigator 1 Novo Nordisk AS $550.39 11/21/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4375 No dispute reported 06/30/2026 706703903
Principal investigator 1 Novo Nordisk AS $11.38 11/21/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4506 No dispute reported 06/30/2026 706704079
Principal investigator 1 Novo Nordisk AS $11.38 11/21/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4506 No dispute reported 06/30/2026 706704081
Principal investigator 1 Novo Nordisk AS $11.38 11/21/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4506 No dispute reported 06/30/2026 706704083
Principal investigator 1 Novo Nordisk AS $11.38 11/21/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4506 No dispute reported 06/30/2026 706704085
Principal investigator 1 Novo Nordisk AS $11.38 11/21/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4506 No dispute reported 06/30/2026 706704087
Principal investigator 1 Novo Nordisk AS $11.38 11/21/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4506 No dispute reported 06/30/2026 706704089
Principal investigator 1 Novo Nordisk AS $11.38 11/21/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4506 No dispute reported 06/30/2026 706704091
Principal investigator 1 Novo Nordisk AS $11.38 11/21/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4506 No dispute reported 06/30/2026 706704093
Principal investigator 1 Novo Nordisk AS $11.38 11/21/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4506 No dispute reported 06/30/2026 706704095
Principal investigator 1 Novo Nordisk AS $11.38 11/21/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4506 No dispute reported 06/30/2026 706704097
Principal investigator 1 Novo Nordisk AS $11.38 11/21/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4506 No dispute reported 06/30/2026 706704099
Principal investigator 1 Novo Nordisk AS $11.38 11/21/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4506 No dispute reported 06/30/2026 706704101
Principal investigator 1 Novo Nordisk AS $11.38 11/21/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4506 No dispute reported 06/30/2026 706704103
Principal investigator 1 Novo Nordisk AS $11.38 11/21/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4506 No dispute reported 06/30/2026 706704105
Principal investigator 1 Novo Nordisk AS $11.38 11/21/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4506 No dispute reported 06/30/2026 706704107
Principal investigator 1 Novo Nordisk AS $11.38 11/21/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4506 No dispute reported 06/30/2026 706704109
Principal investigator 1 Novo Nordisk AS $11.38 11/21/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4506 No dispute reported 06/30/2026 706704111
Principal investigator 1 Novo Nordisk AS $11.38 11/21/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4506 No dispute reported 06/30/2026 706704113
Principal investigator 1 Novo Nordisk AS $11.38 11/21/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4506 No dispute reported 06/30/2026 706704115
Principal investigator 1 Novo Nordisk AS $11.38 11/21/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4506 No dispute reported 06/30/2026 706704117
Principal investigator 1 Novo Nordisk AS $11.38 11/21/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4506 No dispute reported 06/30/2026 706704119
Principal investigator 1 Novo Nordisk AS $6.50 11/21/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4506 No dispute reported 06/30/2026 706704121
Principal investigator 1 Novo Nordisk AS $6.50 11/21/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4506 No dispute reported 06/30/2026 706704123
Principal investigator 1 Novo Nordisk AS $6.50 11/21/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4506 No dispute reported 06/30/2026 706704125
Principal investigator 1 Novo Nordisk AS $6.50 11/21/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4506 No dispute reported 06/30/2026 706704127
Principal investigator 1 Novo Nordisk AS $6.50 11/21/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4506 No dispute reported 06/30/2026 706704129
Principal investigator 1 Novo Nordisk AS $6.50 11/21/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4506 No dispute reported 06/30/2026 706704131
Principal investigator 1 Novo Nordisk AS $6.50 11/21/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4506 No dispute reported 06/30/2026 706704133
Principal investigator 1 Novo Nordisk AS $6.50 11/21/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4506 No dispute reported 06/30/2026 706704135
Principal investigator 1 Novo Nordisk AS $6.50 11/21/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4506 No dispute reported 06/30/2026 706704137
Principal investigator 1 Novo Nordisk AS $6.50 11/21/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4506 No dispute reported 06/30/2026 706704139
Principal investigator 1 Novo Nordisk AS $6.50 11/21/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4506 No dispute reported 06/30/2026 706704141
Principal investigator 1 Novo Nordisk AS $6.50 11/21/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4506 No dispute reported 06/30/2026 706704143
Principal investigator 1 Novo Nordisk AS $6.50 11/21/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4506 No dispute reported 06/30/2026 706704145
Principal investigator 1 Novo Nordisk AS $6.50 11/21/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4506 No dispute reported 06/30/2026 706704147
Principal investigator 1 Novo Nordisk AS $6.50 11/21/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4506 No dispute reported 06/30/2026 706704149
Principal investigator 1 Novo Nordisk AS $6.50 11/21/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4506 No dispute reported 06/30/2026 706704151
Principal investigator 1 Novo Nordisk AS $6.50 11/21/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4506 No dispute reported 06/30/2026 706704153
Principal investigator 1 Novo Nordisk AS $36.00 11/21/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4506 No dispute reported 06/30/2026 706704155
Principal investigator 1 Novo Nordisk AS $36.00 11/21/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4506 No dispute reported 06/30/2026 706704157
Principal investigator 1 Novo Nordisk AS $36.00 11/21/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4506 No dispute reported 06/30/2026 706704159
Principal investigator 1 Novo Nordisk AS $36.00 11/21/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4506 No dispute reported 06/30/2026 706704161
Principal investigator 1 Novo Nordisk AS $36.00 11/21/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4506 No dispute reported 06/30/2026 706704163
Principal investigator 1 Novo Nordisk AS $36.00 11/21/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4506 No dispute reported 06/30/2026 706704165
Principal investigator 1 Novo Nordisk AS $36.00 11/21/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4506 No dispute reported 06/30/2026 706704167
Principal investigator 1 Novo Nordisk AS $36.00 11/21/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4506 No dispute reported 06/30/2026 706704169
Principal investigator 1 Novo Nordisk AS $36.00 11/21/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4506 No dispute reported 06/30/2026 706704171
Principal investigator 1 Novo Nordisk AS $36.00 11/21/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4506 No dispute reported 06/30/2026 706704173
Principal investigator 1 Novo Nordisk AS $2.65 11/21/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4506 No dispute reported 06/30/2026 706704175
Principal investigator 1 Novo Nordisk AS $9.00 11/21/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4506 No dispute reported 06/30/2026 706704177
Principal investigator 1 Novo Nordisk AS $30.00 11/21/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4506 No dispute reported 06/30/2026 706704179
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $7,790.01 11/20/2019 Non-covered Recipient Entity
PMG RESEARCH INC
A Phase 1, Multicenter, Randomized, Open-Label, Parallel-Group, Multi-Dose Study in Patients With Moderate-to-Severe Pain Due to Osteoarthritis of the Knee or Hip to Assess the Patients' Ability to Self-Administer Fasinumab Using an Auto-Injector and to Characterize the Pharmacokinetics of Fasinumab Using Two Different Presentations No dispute reported 06/30/2026 639750093
Principal investigator 1 PFIZER INC. $97.00 11/18/2019 Non-covered Recipient Entity
PMG Research of Wilmington LLC
A PHASE 12 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING FIRSTINHUMAN STUDY TO DESCRIBE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A RESPIRATORY SYNCYTIAL VIRUS RSV VACCINE IN HEALTHY ADULTS No dispute reported 06/30/2026 671684221
Principal investigator 1 PFIZER INC. $52.68 11/18/2019 Non-covered Recipient Entity
PMG Research of Wilmington LLC
A PHASE 12 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING FIRSTINHUMAN STUDY TO DESCRIBE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A RESPIRATORY SYNCYTIAL VIRUS RSV VACCINE IN HEALTHY ADULTS No dispute reported 06/30/2026 671684255
Principal investigator 1 Merck Sharp & Dohme Corporation $16,924.00 11/15/2019 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691501741
Principal investigator 1 Novo Nordisk AS $270.00 11/15/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4373 No dispute reported 06/30/2026 706703763
Principal investigator 1 Novo Nordisk AS $270.00 11/15/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4373 No dispute reported 06/30/2026 706703765
Principal investigator 1 Novo Nordisk AS $270.00 11/15/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4373 No dispute reported 06/30/2026 706703767
Principal investigator 1 Novo Nordisk AS $270.00 11/15/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4373 No dispute reported 06/30/2026 706703769
Principal investigator 1 Novo Nordisk AS $270.00 11/15/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4373 No dispute reported 06/30/2026 706703771
Principal investigator 1 Novo Nordisk AS $270.00 11/15/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4373 No dispute reported 06/30/2026 706703773
Principal investigator 1 Novo Nordisk AS $270.00 11/15/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4373 No dispute reported 06/30/2026 706703775
Principal investigator 1 Novo Nordisk AS $270.00 11/15/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4373 No dispute reported 06/30/2026 706703777
Principal investigator 1 Novo Nordisk AS $8.70 11/15/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 706703909
Principal investigator 1 Novo Nordisk AS $8.70 11/15/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 706703911
Principal investigator 1 Novo Nordisk AS $8.70 11/15/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 706703913
Principal investigator 1 Novo Nordisk AS $8.70 11/15/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 706703915
Principal investigator 1 Novo Nordisk AS $5.10 11/15/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 706703917
Principal investigator 1 Novo Nordisk AS $5.10 11/15/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 706703919
Principal investigator 1 Novo Nordisk AS $5.10 11/15/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 706703921
Principal investigator 1 Novo Nordisk AS $5.10 11/15/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 706703923
Principal investigator 1 Novo Nordisk AS $5.10 11/15/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 706703925
Principal investigator 1 Novo Nordisk AS $5.10 11/15/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 706703927
Principal investigator 1 Novo Nordisk AS $5.10 11/15/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 706703929
Principal investigator 1 Novo Nordisk AS $5.10 11/15/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 706703931
Principal investigator 1 Novo Nordisk AS $5.10 11/15/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 706703933
Principal investigator 1 Novo Nordisk AS $5.10 11/15/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 706703935
Principal investigator 1 Novo Nordisk AS $5.10 11/15/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 706703937
Principal investigator 1 Novo Nordisk AS $5.10 11/15/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 706703939
Principal investigator 1 Novo Nordisk AS $5.10 11/15/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 706703941
Principal investigator 1 Novo Nordisk AS $5.10 11/15/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 706703943
Principal investigator 1 Novo Nordisk AS $5.10 11/15/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 706703945
Principal investigator 1 Novo Nordisk AS $5.10 11/15/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 706703947
Principal investigator 1 Novo Nordisk AS $5.10 11/15/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 706703949
Principal investigator 1 Novo Nordisk AS $5.10 11/15/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 706703951
Principal investigator 1 Novo Nordisk AS $5.10 11/15/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 706703953
Principal investigator 1 Novo Nordisk AS $5.10 11/15/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 706703955
Principal investigator 1 Novo Nordisk AS $5.10 11/15/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 706703957
Principal investigator 1 Novo Nordisk AS $5.10 11/15/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 706703959
Principal investigator 1 Novo Nordisk AS $22.68 11/15/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 706703961
Principal investigator 1 Novo Nordisk AS $22.68 11/15/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 706703963
Principal investigator 1 Novo Nordisk AS $22.68 11/15/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 706703965
Principal investigator 1 Novo Nordisk AS $22.68 11/15/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 706703967
Principal investigator 1 Novo Nordisk AS $22.68 11/15/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 706703969
Principal investigator 1 Novo Nordisk AS $22.68 11/15/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 706703971
Principal investigator 1 Novo Nordisk AS $15.34 11/15/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 706703973
Principal investigator 1 Novo Nordisk AS $11.38 11/15/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 706703975
Principal investigator 1 Novo Nordisk AS $11.38 11/15/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 706703977
Principal investigator 1 Novo Nordisk AS $11.38 11/15/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 706703979
Principal investigator 1 Novo Nordisk AS $11.38 11/15/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 706703981
Principal investigator 1 Novo Nordisk AS $11.38 11/15/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 706703983
Principal investigator 1 Novo Nordisk AS $11.38 11/15/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 706703985
Principal investigator 1 Novo Nordisk AS $11.38 11/15/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 706703987
Principal investigator 1 Novo Nordisk AS $11.38 11/15/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 706703989
Principal investigator 1 Novo Nordisk AS $11.38 11/15/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 706703991
Principal investigator 1 Novo Nordisk AS $11.38 11/15/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 706703993
Principal investigator 1 Novo Nordisk AS $11.38 11/15/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 706703995
Principal investigator 1 Novo Nordisk AS $11.38 11/15/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 706703997
Principal investigator 1 Novo Nordisk AS $11.38 11/15/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 706703999
Principal investigator 1 Novo Nordisk AS $11.38 11/15/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 706704001
Principal investigator 1 Novo Nordisk AS $11.38 11/15/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 706704003
Principal investigator 1 Novo Nordisk AS $11.38 11/15/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 706704005
Principal investigator 1 Novo Nordisk AS $11.38 11/15/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 706704007
Principal investigator 1 Novo Nordisk AS $11.38 11/15/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 706704009
Principal investigator 1 Novo Nordisk AS $11.38 11/15/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 706704011
Principal investigator 1 Novo Nordisk AS $11.38 11/15/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 706704013
Principal investigator 1 Novo Nordisk AS $11.38 11/15/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 706704015
Principal investigator 1 Novo Nordisk AS $8.70 11/15/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 706704067
Principal investigator 1 Novo Nordisk AS $8.70 11/15/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 706704069
Principal investigator 1 Novo Nordisk AS $8.70 11/15/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 706704071
Principal investigator 1 Novo Nordisk AS $8.70 11/15/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 706704073
Principal investigator 1 SANOFI US SERVICES INC. $7,100.00 11/15/2019 Non-covered Recipient Entity
Pmg Research,Incorporation
A 56-week, Multicenter, Double-blind, Placebo-controlled, Randomized Study to Evaluate the Efficacy and Safety of Efpeglenatide Once Weekly in Patients with Type 2 Diabetes Mellitus Inadequately Contr No dispute reported 06/30/2026 691601985
Principal investigator 1 Novo Nordisk AS $56.90 11/13/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 706703761
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $31,833.00 11/13/2019 Non-covered Recipient Entity
PMG RESEARCH INC
A Phase 1, Multicenter, Randomized, Open-Label, Parallel-Group, Multi-Dose Study in Patients With Moderate-to-Severe Pain Due to Osteoarthritis of the Knee or Hip to Assess the Patients' Ability to Self-Administer Fasinumab Using an Auto-Injector and to Characterize the Pharmacokinetics of Fasinumab Using Two Different Presentations No dispute reported 06/30/2026 639750091
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $256.00 11/12/2019 Non-covered Recipient Entity
PMG RESEARCH INC
EFC15294 No dispute reported 06/30/2026 690603599
Principal investigator 1 SANOFI US SERVICES INC. $256.00 11/12/2019 Non-covered Recipient Entity
Pmg Research,Incorporation
A 26-week Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter, Phase 3 Study With a 78-week Extension Period to Evaluate the Efficacy and Bone Safety of Sotagliflozin in Patients No dispute reported 06/30/2026 691610419
Principal investigator 1 Merck Sharp & Dohme Corporation $275.00 11/08/2019 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691538813
Principal investigator 1 Merck Sharp & Dohme Corporation $336.00 11/08/2019 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691538815
Principal investigator 1 Merck Sharp & Dohme Corporation $10.00 11/08/2019 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691539697
Principal investigator 1 Merck Sharp & Dohme Corporation $1,210.00 11/08/2019 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691539801
Principal investigator 1 Merck Sharp & Dohme Corporation $13.00 11/08/2019 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691539803
Principal investigator 1 Merck Sharp & Dohme Corporation $2,640.00 11/08/2019 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691539807
Principal investigator 1 Merck Sharp & Dohme Corporation $35.50 11/08/2019 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691539979
Principal investigator 1 Merck Sharp & Dohme Corporation $38.00 11/08/2019 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691539981
Principal investigator 1 Merck Sharp & Dohme Corporation $68.00 11/08/2019 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691539985
Principal investigator 1 Merck Sharp & Dohme Corporation $95.00 11/08/2019 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691540147
Principal investigator 1 Merck Sharp & Dohme Corporation $7.00 11/08/2019 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691540813
Principal investigator 1 Merck Sharp & Dohme Corporation $33.00 11/08/2019 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691541331
Principal investigator 1 Novo Nordisk AS $90.00 11/08/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4374 No dispute reported 06/30/2026 706703757
Principal investigator 1 Novo Nordisk AS $90.00 11/08/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4374 No dispute reported 06/30/2026 706703759
Principal investigator 1 Novo Nordisk AS $12.75 11/08/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4374 No dispute reported 06/30/2026 706703785
Principal investigator 1 Novo Nordisk AS $12.75 11/08/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4374 No dispute reported 06/30/2026 706703787
Principal investigator 1 Novo Nordisk AS $12.75 11/08/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4374 No dispute reported 06/30/2026 706703789
Principal investigator 1 Novo Nordisk AS $12.75 11/08/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4374 No dispute reported 06/30/2026 706703791
Principal investigator 1 Novo Nordisk AS $12.75 11/08/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4374 No dispute reported 06/30/2026 706703793
Principal investigator 1 Novo Nordisk AS $12.75 11/08/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4374 No dispute reported 06/30/2026 706703795
Principal investigator 1 Novo Nordisk AS $12.75 11/08/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4374 No dispute reported 06/30/2026 706703797
Principal investigator 1 Novo Nordisk AS $12.75 11/08/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4374 No dispute reported 06/30/2026 706703799
Principal investigator 1 Novo Nordisk AS $12.75 11/08/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4374 No dispute reported 06/30/2026 706703801
Principal investigator 1 Novo Nordisk AS $12.75 11/08/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4374 No dispute reported 06/30/2026 706703803
Principal investigator 1 Novo Nordisk AS $12.75 11/08/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4374 No dispute reported 06/30/2026 706703805
Principal investigator 1 Novo Nordisk AS $12.75 11/08/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4374 No dispute reported 06/30/2026 706703807
Principal investigator 1 Novo Nordisk AS $12.75 11/08/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4374 No dispute reported 06/30/2026 706703809
Principal investigator 1 Novo Nordisk AS $12.75 11/08/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4374 No dispute reported 06/30/2026 706703811
Principal investigator 1 Novo Nordisk AS $12.75 11/08/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4374 No dispute reported 06/30/2026 706703813
Principal investigator 1 Novo Nordisk AS $12.75 11/08/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4374 No dispute reported 06/30/2026 706703815
Principal investigator 1 Novo Nordisk AS $12.75 11/08/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4374 No dispute reported 06/30/2026 706703817
Principal investigator 1 Novo Nordisk AS $12.75 11/08/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4374 No dispute reported 06/30/2026 706703819
Principal investigator 1 Novo Nordisk AS $12.75 11/08/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4374 No dispute reported 06/30/2026 706703821
Principal investigator 1 Novo Nordisk AS $12.75 11/08/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4374 No dispute reported 06/30/2026 706703823
Principal investigator 1 Novo Nordisk AS $12.75 11/08/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4374 No dispute reported 06/30/2026 706703825
Principal investigator 1 Novo Nordisk AS $12.75 11/08/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4374 No dispute reported 06/30/2026 706703827
Principal investigator 1 Novo Nordisk AS $28.45 11/08/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4374 No dispute reported 06/30/2026 706703829
Principal investigator 1 Novo Nordisk AS $28.45 11/08/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4374 No dispute reported 06/30/2026 706703831
Principal investigator 1 Novo Nordisk AS $28.45 11/08/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4374 No dispute reported 06/30/2026 706703833
Principal investigator 1 Novo Nordisk AS $28.45 11/08/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4374 No dispute reported 06/30/2026 706703835
Principal investigator 1 Novo Nordisk AS $28.45 11/08/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4374 No dispute reported 06/30/2026 706703837
Principal investigator 1 Novo Nordisk AS $28.45 11/08/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4374 No dispute reported 06/30/2026 706703839
Principal investigator 1 Novo Nordisk AS $28.45 11/08/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4374 No dispute reported 06/30/2026 706703841
Principal investigator 1 Novo Nordisk AS $28.45 11/08/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4374 No dispute reported 06/30/2026 706703843
Principal investigator 1 Novo Nordisk AS $28.45 11/08/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4374 No dispute reported 06/30/2026 706703845
Principal investigator 1 Novo Nordisk AS $28.45 11/08/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4374 No dispute reported 06/30/2026 706703847
Principal investigator 1 Novo Nordisk AS $28.45 11/08/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4374 No dispute reported 06/30/2026 706703849
Principal investigator 1 Novo Nordisk AS $28.45 11/08/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4374 No dispute reported 06/30/2026 706703851
Principal investigator 1 Novo Nordisk AS $28.45 11/08/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4374 No dispute reported 06/30/2026 706703853
Principal investigator 1 Novo Nordisk AS $28.45 11/08/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4374 No dispute reported 06/30/2026 706703855
Principal investigator 1 Novo Nordisk AS $28.45 11/08/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4374 No dispute reported 06/30/2026 706703857
Principal investigator 1 Novo Nordisk AS $28.45 11/08/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4374 No dispute reported 06/30/2026 706703859
Principal investigator 1 Novo Nordisk AS $28.45 11/08/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4374 No dispute reported 06/30/2026 706703861
Principal investigator 1 Novo Nordisk AS $28.45 11/08/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4374 No dispute reported 06/30/2026 706703863
Principal investigator 1 Novo Nordisk AS $28.45 11/08/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4374 No dispute reported 06/30/2026 706703865
Principal investigator 1 Novo Nordisk AS $28.45 11/08/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4374 No dispute reported 06/30/2026 706703867
Principal investigator 1 Novo Nordisk AS $28.45 11/08/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4374 No dispute reported 06/30/2026 706703869
Principal investigator 1 Novo Nordisk AS $21.75 11/08/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4374 No dispute reported 06/30/2026 706703871
Principal investigator 1 Novo Nordisk AS $21.75 11/08/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4374 No dispute reported 06/30/2026 706703873
Principal investigator 1 Novo Nordisk AS $21.75 11/08/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4374 No dispute reported 06/30/2026 706703875
Principal investigator 1 Novo Nordisk AS $21.75 11/08/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4374 No dispute reported 06/30/2026 706703877
Principal investigator 1 Novo Nordisk AS $21.75 11/08/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4374 No dispute reported 06/30/2026 706703879
Principal investigator 1 Novo Nordisk AS $21.75 11/08/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4374 No dispute reported 06/30/2026 706703881
Principal investigator 1 Novo Nordisk AS $21.75 11/08/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4374 No dispute reported 06/30/2026 706703883
Principal investigator 1 Novo Nordisk AS $21.75 11/08/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4374 No dispute reported 06/30/2026 706703885
Principal investigator 1 Novo Nordisk AS $90.00 11/08/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4374 No dispute reported 06/30/2026 706703887
Principal investigator 1 Novo Nordisk AS $90.00 11/08/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4374 No dispute reported 06/30/2026 706703889
Principal investigator 1 Novo Nordisk AS $90.00 11/08/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4374 No dispute reported 06/30/2026 706703891
Principal investigator 1 Novo Nordisk AS $90.00 11/08/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4374 No dispute reported 06/30/2026 706703893
Principal investigator 1 Novo Nordisk AS $90.00 11/08/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4374 No dispute reported 06/30/2026 706703895
Principal investigator 1 Novo Nordisk AS $90.00 11/08/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4374 No dispute reported 06/30/2026 706703897
Principal investigator 1 Novo Nordisk AS $90.00 11/08/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4374 No dispute reported 06/30/2026 706703899
Principal investigator 1 Novo Nordisk AS $90.00 11/08/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4374 No dispute reported 06/30/2026 706703901
Principal investigator 1 Novo Nordisk AS $49.98 11/08/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 706703907
Principal investigator 1 Novo Nordisk AS $5.69 11/07/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4375 No dispute reported 06/30/2026 706704017
Principal investigator 1 Novo Nordisk AS $5.69 11/07/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4375 No dispute reported 06/30/2026 706704019
Principal investigator 1 Novo Nordisk AS $5.69 11/07/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4375 No dispute reported 06/30/2026 706704021
Principal investigator 1 Novo Nordisk AS $5.69 11/07/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4375 No dispute reported 06/30/2026 706704023
Principal investigator 1 Novo Nordisk AS $5.69 11/07/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4375 No dispute reported 06/30/2026 706704025
Principal investigator 1 Novo Nordisk AS $5.69 11/07/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4375 No dispute reported 06/30/2026 706704027
Principal investigator 1 Novo Nordisk AS $5.69 11/07/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4375 No dispute reported 06/30/2026 706704029
Principal investigator 1 Novo Nordisk AS $5.69 11/07/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4375 No dispute reported 06/30/2026 706704031
Principal investigator 1 Novo Nordisk AS $5.69 11/07/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4375 No dispute reported 06/30/2026 706704033
Principal investigator 1 Novo Nordisk AS $5.69 11/07/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4375 No dispute reported 06/30/2026 706704035
Principal investigator 1 Novo Nordisk AS $5.69 11/07/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4375 No dispute reported 06/30/2026 706704037
Principal investigator 1 Novo Nordisk AS $5.69 11/07/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4375 No dispute reported 06/30/2026 706704039
Principal investigator 1 Novo Nordisk AS $5.69 11/07/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4375 No dispute reported 06/30/2026 706704041
Principal investigator 1 Novo Nordisk AS $5.69 11/07/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4375 No dispute reported 06/30/2026 706704043
Principal investigator 1 Novo Nordisk AS $5.69 11/07/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4375 No dispute reported 06/30/2026 706704045
Principal investigator 1 Novo Nordisk AS $5.69 11/07/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4375 No dispute reported 06/30/2026 706704047
Principal investigator 1 Novo Nordisk AS $5.69 11/07/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4375 No dispute reported 06/30/2026 706704049
Principal investigator 1 Novo Nordisk AS $5.69 11/07/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4375 No dispute reported 06/30/2026 706704051
Principal investigator 1 Novo Nordisk AS $5.69 11/07/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4375 No dispute reported 06/30/2026 706704053
Principal investigator 1 Novo Nordisk AS $5.69 11/07/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4375 No dispute reported 06/30/2026 706704055
Principal investigator 1 Novo Nordisk AS $5.69 11/07/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4375 No dispute reported 06/30/2026 706704057
Principal investigator 1 Novo Nordisk AS $56.90 11/06/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 706704075
Principal investigator 1 Novo Nordisk AS $32.50 11/06/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 706704077
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $908.51 11/06/2019 Non-covered Recipient Entity
PMG RESEARCH INC
PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO AND NSAID CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP No dispute reported 06/30/2026 639750089
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $14,650.00 11/04/2019 Non-covered Recipient Entity
PMG RESEARCH INC
EFC15294 No dispute reported 06/30/2026 690603595
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $14,650.00 11/04/2019 Non-covered Recipient Entity
PMG RESEARCH INC
EFC15294 No dispute reported 06/30/2026 690603597
Principal investigator 1 SANOFI US SERVICES INC. $2,000.00 11/04/2019 Non-covered Recipient Entity
Pmg Research,Incorporation
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin Added to Metformin in Patients With Type 2 Diabetes Mellitus Who No dispute reported 06/30/2026 691610391
Principal investigator 1 SANOFI US SERVICES INC. $14,650.00 11/04/2019 Non-covered Recipient Entity
Pmg Research,Incorporation
A 26-week Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter, Phase 3 Study With a 78-week Extension Period to Evaluate the Efficacy and Bone Safety of Sotagliflozin in Patients No dispute reported 06/30/2026 691610409
Principal investigator 1 PFIZER INC. $14,819.32 11/02/2019 Non-covered Recipient Entity
PMG Research of Wilmington LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF 2 DOSES COMPARED TO 3 DOSES OF CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671676805
Principal investigator 1 PFIZER INC. $1,256.84 11/02/2019 Non-covered Recipient Entity
PMG Research of Hickory LLC
A PHASE 12 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING FIRSTINHUMAN STUDY TO DESCRIBE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A RESPIRATORY SYNCYTIAL VIRUS RSV VACCINE IN HEALTHY ADULTS No dispute reported 06/30/2026 671678611
Principal investigator 1 PFIZER INC. $3,270.40 11/02/2019 Non-covered Recipient Entity
PMG Research of Wilmington LLC
A PHASE 3 RANDOMIZED OPENLABEL TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS 65 YEARS OF AGE WITH PRIOR PNEUMOCOCCAL VACCINATION No dispute reported 06/30/2026 671680079
Principal investigator 1 PFIZER INC. $3,597.44 11/02/2019 Non-covered Recipient Entity
PMG Research of Wilmington LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINENAIVE ADULTS 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671683979
Principal investigator 1 Novo Nordisk AS $49.98 11/01/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 706703739
Principal investigator 1 PFIZER INC. $23.75 10/31/2019 Non-covered Recipient Entity
PMG Research of Wilmington
A PHASE 2 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF TWO 3DOSE REGIMENS OF A CLOSTRIDIUM DIFFICILE VACCINE IN HEALTHY ADULTS AGED 65 TO 85 YEARS No dispute reported 06/30/2026 671671213
Principal investigator 1 PFIZER INC. $194.00 10/31/2019 Non-covered Recipient Entity
PMG Research of Wilmington LLC
A PHASE 12 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING FIRSTINHUMAN STUDY TO DESCRIBE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A RESPIRATORY SYNCYTIAL VIRUS RSV VACCINE IN HEALTHY ADULTS No dispute reported 06/30/2026 671684379
Principal investigator 1 PFIZER INC. $35.12 10/31/2019 Non-covered Recipient Entity
PMG Research of Wilmington LLC
A PHASE 12 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING FIRSTINHUMAN STUDY TO DESCRIBE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A RESPIRATORY SYNCYTIAL VIRUS RSV VACCINE IN HEALTHY ADULTS No dispute reported 06/30/2026 671684411
Principal investigator 1 PFIZER INC. $13.45 10/31/2019 Non-covered Recipient Entity
PMG Research of Wilmington LLC
A PHASE 12 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING FIRSTINHUMAN STUDY TO DESCRIBE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A RESPIRATORY SYNCYTIAL VIRUS RSV VACCINE IN HEALTHY ADULTS No dispute reported 06/30/2026 671684485
Principal investigator 1 GlaxoSmithKline, LLC. $2,317.50 10/30/2019 Non-covered Recipient Entity
PMG RESEARCH
RSV OA=ADJ-002 No dispute reported 06/30/2026 669963059
Principal investigator 1 Novo Nordisk AS $24.99 10/30/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 706703689
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $54.57 10/30/2019 Non-covered Recipient Entity
PMG RESEARCH INC
A Phase 1, Multicenter, Randomized, Open-Label, Parallel-Group, Multi-Dose Study in Patients With Moderate-to-Severe Pain Due to Osteoarthritis of the Knee or Hip to Assess the Patients' Ability to Self-Administer Fasinumab Using an Auto-Injector and to Characterize the Pharmacokinetics of Fasinumab Using Two Different Presentations No dispute reported 06/30/2026 639750085
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $20,756.94 10/30/2019 Non-covered Recipient Entity
PMG RESEARCH INC
A Phase 1, Multicenter, Randomized, Open-Label, Parallel-Group, Multi-Dose Study in Patients With Moderate-to-Severe Pain Due to Osteoarthritis of the Knee or Hip to Assess the Patients' Ability to Self-Administer Fasinumab Using an Auto-Injector and to Characterize the Pharmacokinetics of Fasinumab Using Two Different Presentations No dispute reported 06/30/2026 639750087
Principal investigator 1 Novo Nordisk AS $2,120.57 10/29/2019 Non-covered Recipient Entity
PMG RESEARCH INC
NN9535-4506 No dispute reported 06/30/2026 692464027
Principal investigator 1 Novo Nordisk AS $3,439.70 10/29/2019 Non-covered Recipient Entity
PMG RESEARCH INC
NN9536-4374 No dispute reported 06/30/2026 692464119
Principal investigator 1 Novo Nordisk AS $18,624.79 10/29/2019 Non-covered Recipient Entity
PMG RESEARCH INC
NN9536-4576 No dispute reported 06/30/2026 692464121
Principal investigator 1 Novo Nordisk AS $13,654.85 10/29/2019 Non-covered Recipient Entity
PMG RESEARCH INC
NN9536-4373 No dispute reported 06/30/2026 692464123
Principal investigator 1 Novo Nordisk AS $2,272.73 10/29/2019 Non-covered Recipient Entity
PMG RESEARCH INC
EX9924-4473 No dispute reported 06/30/2026 692464125
Principal investigator 1 Novo Nordisk AS $2,565.86 10/29/2019 Non-covered Recipient Entity
PMG RESEARCH INC
EX9536-4388 No dispute reported 06/30/2026 692464127
Principal investigator 1 Novo Nordisk AS $2,400.00 10/29/2019 Non-covered Recipient Entity
PMG RESEARCH INC
EX9536-4388 No dispute reported 06/30/2026 692464129
Principal investigator 1 Novo Nordisk AS $11,728.39 10/29/2019 Non-covered Recipient Entity
PMG RESEARCH INC
NN9536-4375 No dispute reported 06/30/2026 692464131
Principal investigator 1 Novo Nordisk AS $11,845.19 10/29/2019 Non-covered Recipient Entity
PMG RESEARCH INC
EX9536-4388 No dispute reported 06/30/2026 692464133
Principal investigator 1 Novo Nordisk AS $24.99 10/25/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 706703687
Principal investigator 1 SANOFI US SERVICES INC. $1,143.45 10/24/2019 Non-covered Recipient Entity
Pmg Research,Incorporation
A Randomized, Double-blind, Placebo-controlled, 3-arm, Parallel-group 52-week Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin in Patients With Type 2 Diabetes Mellitus and Moder No dispute reported 06/30/2026 691610319
Principal investigator 1 GlaxoSmithKline, LLC. $1,837.80 10/23/2019 Non-covered Recipient Entity
PMG RESEARCH
RSV OA=ADJ-002 No dispute reported 06/30/2026 669969759
Principal investigator 1 PFIZER INC. $25,585.94 10/23/2019 Non-covered Recipient Entity
PMG Research of Wilmington LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF 2 DOSES COMPARED TO 3 DOSES OF CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671669415
Principal investigator 1 PFIZER INC. $800.81 10/23/2019 Non-covered Recipient Entity
PMG RESEARCH INC
A PHASE 12 RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY ADULTS 50 THROUGH 85 YEARS OF AGE No dispute reported 06/30/2026 671676575
Principal investigator 1 PFIZER INC. $10,683.14 10/23/2019 Non-covered Recipient Entity
PMG Research of Hickory LLC
A PHASE 12 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING FIRSTINHUMAN STUDY TO DESCRIBE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A RESPIRATORY SYNCYTIAL VIRUS RSV VACCINE IN HEALTHY ADULTS No dispute reported 06/30/2026 671676941
Principal investigator 1 PFIZER INC. $3,533.31 10/23/2019 Non-covered Recipient Entity
PMG Research of Wilmington LLC
A PHASE 3 RANDOMIZED OPENLABEL TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS 65 YEARS OF AGE WITH PRIOR PNEUMOCOCCAL VACCINATION No dispute reported 06/30/2026 671679669
Principal investigator 1 PFIZER INC. $6,213.76 10/23/2019 Non-covered Recipient Entity
PMG Research of Wilmington LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINENAIVE ADULTS 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671683977
Principal investigator 1 PFIZER INC. $1,962.24 10/23/2019 Non-covered Recipient Entity
PMG Research of Wilmington LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF 3 LOTS OF 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINENAIVE ADULTS 18 THROUGH 49 YEARS OF AGE No dispute reported 06/30/2026 671684047
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,105.00 10/23/2019 Non-covered Recipient Entity
PMG RESEARCH INC
PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO AND NSAID CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP No dispute reported 06/30/2026 639750081
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $28,685.95 10/23/2019 Non-covered Recipient Entity
PMG RESEARCH INC
PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO AND NSAID CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP No dispute reported 06/30/2026 639750083
Principal investigator 1 Novo Nordisk AS $17.85 10/22/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 706703691
Principal investigator 1 Novo Nordisk AS $82.88 10/22/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 706703693
Principal investigator 1 Novo Nordisk AS $30.45 10/22/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 706703695
Principal investigator 1 AstraZeneca Pharmaceuticals LP $12,092.40 10/18/2019 Non-covered Recipient Entity
Pmg Research Of Charlotte Llc
A Long Term Outcomes Study to Assess STatin Residual Risk Reduction with EpaNova in HiGh Cardiovascular Risk PatienTs with Hypertriglyceridemia No dispute reported 06/30/2026 684988647
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,350.00 10/16/2019 Non-covered Recipient Entity
PMG RESEARCH INC
PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO AND NSAID CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP No dispute reported 06/30/2026 639750079
Principal investigator 1 Merck Sharp & Dohme Corporation $23,185.00 10/11/2019 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691429939
Principal investigator 1 Novo Nordisk AS $24.99 10/10/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 706703685
Principal investigator 1 PFIZER INC. $40,552.96 10/10/2019 Non-covered Recipient Entity
PMG Research of Wilmington LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF 3 LOTS OF 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINENAIVE ADULTS 18 THROUGH 49 YEARS OF AGE No dispute reported 06/30/2026 671683833
Principal investigator 1 PFIZER INC. $8,096.91 10/09/2019 Non-covered Recipient Entity
PMG RESEARCH INC
A PHASE 12 RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY ADULTS 50 THROUGH 85 YEARS OF AGE No dispute reported 06/30/2026 671673415
Principal investigator 1 PFIZER INC. $3,732.09 10/09/2019 Non-covered Recipient Entity
PMG Research of Wilmington LLC
A PHASE 3 RANDOMIZED OPENLABEL TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS 65 YEARS OF AGE WITH PRIOR PNEUMOCOCCAL VACCINATION No dispute reported 06/30/2026 671679517
Principal investigator 1 PFIZER INC. $11,438.91 10/09/2019 Non-covered Recipient Entity
PMG Research of Wilmington LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINENAIVE ADULTS 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671682989
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,000.00 10/09/2019 Non-covered Recipient Entity
PMG RESEARCH INC
A Phase 1, Multicenter, Randomized, Open-Label, Parallel-Group, Multi-Dose Study in Patients With Moderate-to-Severe Pain Due to Osteoarthritis of the Knee or Hip to Assess the Patients' Ability to Self-Administer Fasinumab Using an Auto-Injector and to Characterize the Pharmacokinetics of Fasinumab Using Two Different Presentations No dispute reported 06/30/2026 639750071
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,125.00 10/09/2019 Non-covered Recipient Entity
PMG RESEARCH INC
A Phase 1, Multicenter, Randomized, Open-Label, Parallel-Group, Multi-Dose Study in Patients With Moderate-to-Severe Pain Due to Osteoarthritis of the Knee or Hip to Assess the Patients' Ability to Self-Administer Fasinumab Using an Auto-Injector and to Characterize the Pharmacokinetics of Fasinumab Using Two Different Presentations No dispute reported 06/30/2026 639750073
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,891.70 10/09/2019 Non-covered Recipient Entity
PMG RESEARCH INC
A Phase 1, Multicenter, Randomized, Open-Label, Parallel-Group, Multi-Dose Study in Patients With Moderate-to-Severe Pain Due to Osteoarthritis of the Knee or Hip to Assess the Patients' Ability to Self-Administer Fasinumab Using an Auto-Injector and to Characterize the Pharmacokinetics of Fasinumab Using Two Different Presentations No dispute reported 06/30/2026 639750075
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $66,151.65 10/09/2019 Non-covered Recipient Entity
PMG RESEARCH INC
A Phase 1, Multicenter, Randomized, Open-Label, Parallel-Group, Multi-Dose Study in Patients With Moderate-to-Severe Pain Due to Osteoarthritis of the Knee or Hip to Assess the Patients' Ability to Self-Administer Fasinumab Using an Auto-Injector and to Characterize the Pharmacokinetics of Fasinumab Using Two Different Presentations No dispute reported 06/30/2026 639750077
Principal investigator 1 SANOFI US SERVICES INC. $8,606.50 10/09/2019 Non-covered Recipient Entity
Pmg Research,Incorporation
A 56-week, Multicenter, Double-blind, Placebo-controlled, Randomized Study to Evaluate the Efficacy and Safety of Efpeglenatide Once Weekly in Patients with Type 2 Diabetes Mellitus Inadequately Contr No dispute reported 06/30/2026 691601979
Principal investigator 1 Merck Sharp & Dohme Corporation $17.60 10/08/2019 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691539805
Principal investigator 1 Merck Sharp & Dohme Corporation $346.50 10/08/2019 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691539977
Principal investigator 1 Merck Sharp & Dohme Corporation $60.50 10/08/2019 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691539983
Principal investigator 1 Novo Nordisk AS $23.06 10/08/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4506 No dispute reported 06/30/2026 706703729
Principal investigator 1 GlaxoSmithKline, LLC. $6,487.20 10/07/2019 Non-covered Recipient Entity
PMG RESEARCH
RSV OA=ADJ-002 No dispute reported 06/30/2026 669967751
Principal investigator 1 Novo Nordisk AS $39.75 10/07/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 706703697
Principal investigator 1 Novo Nordisk AS $80.20 10/07/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 706703699
Principal investigator 1 Novo Nordisk AS $73.50 10/07/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 706703701
Principal investigator 1 Novo Nordisk AS $450.00 10/07/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 706703703
Principal investigator 1 Novo Nordisk AS $48.75 10/07/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 706703705
Principal investigator 1 Novo Nordisk AS $73.50 10/07/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 706703707
Principal investigator 1 Novo Nordisk AS $540.00 10/07/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 706703709
Principal investigator 1 Novo Nordisk AS $45.00 10/07/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 706703711
Principal investigator 1 Novo Nordisk AS $13.25 10/07/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 706703713
Principal investigator 1 Novo Nordisk AS $2.80 10/07/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 706703715
Principal investigator 1 Novo Nordisk AS $24.50 10/07/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 706703717
Principal investigator 1 Novo Nordisk AS $150.00 10/07/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 706703719
Principal investigator 1 Novo Nordisk AS $16.25 10/07/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 706703721
Principal investigator 1 Novo Nordisk AS $24.50 10/07/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 706703723
Principal investigator 1 Novo Nordisk AS $90.00 10/07/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 706703725
Principal investigator 1 Novo Nordisk AS $23.06 10/04/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4506 No dispute reported 06/30/2026 706703727
Principal investigator 1 PFIZER INC. $10,968.59 10/04/2019 Non-covered Recipient Entity
PMG Research of Wilmington LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF 2 DOSES COMPARED TO 3 DOSES OF CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671669093
Principal investigator 1 PFIZER INC. $6,284.20 10/04/2019 Non-covered Recipient Entity
PMG Research of Hickory LLC
A PHASE 12 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING FIRSTINHUMAN STUDY TO DESCRIBE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A RESPIRATORY SYNCYTIAL VIRUS RSV VACCINE IN HEALTHY ADULTS No dispute reported 06/30/2026 671677829
Principal investigator 1 GlaxoSmithKline, LLC. $1,393.20 10/02/2019 Non-covered Recipient Entity
PMG RESEARCH
RSV OA=ADJ-002 No dispute reported 06/30/2026 669965259
Principal investigator 1 GlaxoSmithKline, LLC. $5,355.90 10/02/2019 Non-covered Recipient Entity
PMG RESEARCH
RSV OA=ADJ-002 No dispute reported 06/30/2026 669965429
Principal investigator 1 GlaxoSmithKline, LLC. $2,529.00 10/02/2019 Non-covered Recipient Entity
PMG RESEARCH
RSV OA=ADJ-002 No dispute reported 06/30/2026 669966135
Principal investigator 1 GlaxoSmithKline, LLC. $1,393.20 10/02/2019 Non-covered Recipient Entity
PMG RESEARCH
RSV OA=ADJ-002 No dispute reported 06/30/2026 669973727
Principal investigator 1 PFIZER INC. $750.00 10/02/2019 Non-covered Recipient Entity
PMG RESEARCH INC
A PHASE 12 RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY ADULTS 50 THROUGH 85 YEARS OF AGE No dispute reported 06/30/2026 671673697
Principal investigator 1 SANOFI US SERVICES INC. $648.28 10/02/2019 Non-covered Recipient Entity
Pmg Research Inc
Six-month, Randomized, Open-label, Parallel-group Comparison of SAR341402 to NovoLog/NovoRapid in Adult Patients With Diabetes Also Using Insulin Glargine, With a 6-month Safety Extension Period No dispute reported 06/30/2026 691594683
Principal investigator 1 SANOFI US SERVICES INC. $1,350.00 10/01/2019 Non-covered Recipient Entity
Pmg Research,Incorporation
A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin in Patients With Type 2 Diabetes Who Have Inadequate Glyc No dispute reported 06/30/2026 691610239
Principal investigator 1 GlaxoSmithKline, LLC. $3,710.70 09/30/2019 Non-covered Recipient Entity
PMG RESEARCH
RSV OA=ADJ-002 No dispute reported 06/30/2026 669968385
Principal investigator 1 SANOFI US SERVICES INC. $95.00 09/30/2019 Non-covered Recipient Entity
Pmg Research,Incorporation
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin Added to Metformin in Patients With Type 2 Diabetes Mellitus Who No dispute reported 06/30/2026 691610235
Principal investigator 1 Novo Nordisk AS $6,297.92 09/26/2019 Non-covered Recipient Entity
PMG RESEARCH INC
NN9535-4506 No dispute reported 06/30/2026 692464033
Principal investigator 1 Novo Nordisk AS $15,419.72 09/26/2019 Non-covered Recipient Entity
PMG RESEARCH INC
NN9536-4375 No dispute reported 06/30/2026 692464139
Principal investigator 1 Novo Nordisk AS $187.50 09/26/2019 Non-covered Recipient Entity
PMG RESEARCH INC
NN9536-4375 No dispute reported 06/30/2026 692464141
Principal investigator 1 Novo Nordisk AS $9,442.18 09/26/2019 Non-covered Recipient Entity
PMG RESEARCH INC
EX9536-4388 No dispute reported 06/30/2026 692464147
Principal investigator 1 Novo Nordisk AS $4,962.56 09/26/2019 Non-covered Recipient Entity
PMG RESEARCH INC
NN9536-4374 No dispute reported 06/30/2026 692464153
Principal investigator 1 Novo Nordisk AS $2,500.00 09/26/2019 Non-covered Recipient Entity
PMG RESEARCH INC
NN9536-4576 No dispute reported 06/30/2026 692464155
Principal investigator 1 Novo Nordisk AS $500.00 09/26/2019 Non-covered Recipient Entity
PMG RESEARCH INC
NN9536-4576 No dispute reported 06/30/2026 692464157
Principal investigator 1 Novo Nordisk AS $19,802.84 09/26/2019 Non-covered Recipient Entity
PMG RESEARCH INC
NN9536-4373 No dispute reported 06/30/2026 692464163
Principal investigator 1 Novo Nordisk AS $2,500.00 09/26/2019 Non-covered Recipient Entity
PMG RESEARCH INC
EX9924-4473 No dispute reported 06/30/2026 692464165
Principal investigator 1 Novo Nordisk AS $500.00 09/26/2019 Non-covered Recipient Entity
PMG RESEARCH INC
EX9924-4473 No dispute reported 06/30/2026 692464167
Principal investigator 1 SANOFI US SERVICES INC. $931.00 09/26/2019 Non-covered Recipient Entity
Pmg Research,Incorporation
A 26-week Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter, Phase 3 Study With a 78-week Extension Period to Evaluate the Efficacy and Bone Safety of Sotagliflozin in Patients No dispute reported 06/30/2026 691610229
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,280.24 09/25/2019 Non-covered Recipient Entity
PMG RESEARCH INC
PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO AND NSAID CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP No dispute reported 06/30/2026 639750069
Principal investigator 1 Novo Nordisk AS $2.65 09/20/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4506 No dispute reported 06/30/2026 706703643
Principal investigator 1 Novo Nordisk AS $24.99 09/20/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4506 No dispute reported 06/30/2026 706703645
Principal investigator 1 Novo Nordisk AS $4.50 09/20/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4506 No dispute reported 06/30/2026 706703647
Principal investigator 1 Novo Nordisk AS $30.00 09/20/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4506 No dispute reported 06/30/2026 706703649
Principal investigator 1 Novo Nordisk AS $3.25 09/20/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4506 No dispute reported 06/30/2026 706703651
Principal investigator 1 Novo Nordisk AS $4.90 09/20/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4506 No dispute reported 06/30/2026 706703653
Principal investigator 1 Novo Nordisk AS $18.00 09/20/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4506 No dispute reported 06/30/2026 706703655
Principal investigator 1 Novo Nordisk AS $24.99 09/20/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 706703671
Principal investigator 1 PFIZER INC. $27,076.80 09/20/2019 Non-covered Recipient Entity
PMG Research of Wilmington LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF 2 DOSES COMPARED TO 3 DOSES OF CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671670617
Principal investigator 1 PFIZER INC. $750.00 09/20/2019 Non-covered Recipient Entity
PMG Research of Charlotte
PHASE III LOT CONSISTENCY TRIAL No dispute reported 06/30/2026 671677509
Principal investigator 1 PFIZER INC. $15,658.10 09/20/2019 Non-covered Recipient Entity
PMG Research of Wilmington LLC
A PHASE 3 RANDOMIZED OPENLABEL TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS 65 YEARS OF AGE WITH PRIOR PNEUMOCOCCAL VACCINATION No dispute reported 06/30/2026 671680075
Principal investigator 1 PFIZER INC. $8,176.00 09/20/2019 Non-covered Recipient Entity
PMG Research of Wilmington LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINENAIVE ADULTS 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671682987
Principal investigator 1 GlaxoSmithKline, LLC. $1,439.10 09/18/2019 Non-covered Recipient Entity
PMG RESEARCH
RSV OA=ADJ-002 No dispute reported 06/30/2026 669962927
Principal investigator 1 GlaxoSmithKline, LLC. $5,213.70 09/18/2019 Non-covered Recipient Entity
PMG RESEARCH
RSV OA=ADJ-002 No dispute reported 06/30/2026 669965067
Principal investigator 1 SANOFI US SERVICES INC. $8,003.25 09/18/2019 Non-covered Recipient Entity
Pmg Research Of Winstonsalem
A 56-week, Multicenter, Double-blind, Placebo-controlled, Randomized Study to Evaluate the Efficacy and Safety of Efpeglenatide Once Weekly in Patients with Type 2 Diabetes Mellitus Inadequately Contr No dispute reported 06/30/2026 691575868
Principal investigator 1 Novo Nordisk AS $85.32 09/16/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4373 No dispute reported 06/30/2026 706703663
Principal investigator 1 Novo Nordisk AS $25.50 09/12/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 706703657
Principal investigator 1 Novo Nordisk AS $56.90 09/12/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 706703659
Principal investigator 1 Novo Nordisk AS $32.50 09/12/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 706703661
Principal investigator 1 SANOFI US SERVICES INC. $34,682.00 09/12/2019 Non-covered Recipient Entity
Pmg Research,Incorporation
A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin in Patients With Type 2 Diabetes Who Have Inadequate Glyc No dispute reported 06/30/2026 691610225
Principal investigator 1 PFIZER INC. $628.42 09/11/2019 Non-covered Recipient Entity
PMG RESEARCH INC
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671668691
Principal investigator 1 Merck Sharp & Dohme Corporation $340.00 09/10/2019 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691451805
Principal investigator 1 Merck Sharp & Dohme Corporation $190.00 09/10/2019 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691451825
Principal investigator 1 Merck Sharp & Dohme Corporation $408.60 09/10/2019 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691452375
Principal investigator 1 Merck Sharp & Dohme Corporation $658.90 09/10/2019 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691452459
Principal investigator 1 Merck Sharp & Dohme Corporation $23,160.00 09/09/2019 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691449661
Principal investigator 1 Novo Nordisk AS $10,848.82 09/05/2019 Non-covered Recipient Entity
PMG RESEARCH INC
NN9536-4375 No dispute reported 06/30/2026 692464137
Principal investigator 1 Novo Nordisk AS $43.50 09/04/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 706704197
Principal investigator 1 Novo Nordisk AS $56.90 09/04/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 706704199
Principal investigator 1 Novo Nordisk AS $3.05 09/04/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 706704201
Principal investigator 1 Novo Nordisk AS $76.70 09/04/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 706704203
Principal investigator 1 Novo Nordisk AS $118.40 09/04/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 706704205
Principal investigator 1 Novo Nordisk AS $25.50 09/04/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4576 No dispute reported 06/30/2026 706704207
Principal investigator 1 SANOFI US SERVICES INC. $20,556.50 09/04/2019 Non-covered Recipient Entity
Pmg Research Of Winstonsalem
A 56-week, Multicenter, Double-blind, Placebo-controlled, Randomized Study to Evaluate the Efficacy and Safety of Efpeglenatide Once Weekly in Patients with Type 2 Diabetes Mellitus Inadequately Contr No dispute reported 06/30/2026 691578047
Principal investigator 1 GlaxoSmithKline, LLC. $1,176.30 09/03/2019 Non-covered Recipient Entity
PMG RESEARCH
RSV OA=ADJ-002 No dispute reported 06/30/2026 669964555
Principal investigator 1 GlaxoSmithKline, LLC. $1,439.10 09/03/2019 Non-covered Recipient Entity
PMG RESEARCH
RSV OA=ADJ-002 No dispute reported 06/30/2026 669968381
Principal investigator 1 GlaxoSmithKline, LLC. $1,135.80 09/03/2019 Non-covered Recipient Entity
PMG RESEARCH
RSV OA=ADJ-002 No dispute reported 06/30/2026 669975681
Principal investigator 1 Novo Nordisk AS $7,885.74 08/30/2019 Non-covered Recipient Entity
PMG RESEARCH INC
EX9536-4388 No dispute reported 06/30/2026 692464145
Principal investigator 1 Novo Nordisk AS $7,526.81 08/30/2019 Non-covered Recipient Entity
PMG RESEARCH INC
NN9536-4374 No dispute reported 06/30/2026 692464151
Principal investigator 1 Novo Nordisk AS $11,907.93 08/30/2019 Non-covered Recipient Entity
PMG RESEARCH INC
NN9536-4373 No dispute reported 06/30/2026 692464161
Principal investigator 1 Novo Nordisk AS $2,500.00 08/30/2019 Non-covered Recipient Entity
PMG RESEARCH INC
NN9535-4321 No dispute reported 06/30/2026 692464169
Principal investigator 1 Novo Nordisk AS $500.00 08/30/2019 Non-covered Recipient Entity
PMG RESEARCH INC
NN9535-4321 No dispute reported 06/30/2026 692464171
Principal investigator 1 Novo Nordisk AS $24.99 08/30/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 706703639
Principal investigator 1 Novo Nordisk AS $6.99 08/28/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4375 No dispute reported 06/30/2026 706703637
Principal investigator 1 PFIZER INC. $20,037.69 08/28/2019 Non-covered Recipient Entity
PMG Research of Wilmington LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF 2 DOSES COMPARED TO 3 DOSES OF CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671675733
Principal investigator 1 PFIZER INC. $3,725.68 08/28/2019 Non-covered Recipient Entity
PMG RESEARCH INC
A PHASE 2 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF TWO 3DOSE REGIMENS OF A CLOSTRIDIUM DIFFICILE VACCINE IN HEALTHY ADULTS AGED 65 TO 85 YEARS No dispute reported 06/30/2026 671678629
Principal investigator 1 PFIZER INC. $7,061.45 08/28/2019 Non-covered Recipient Entity
PMG Research of Wilmington LLC
A PHASE 3 RANDOMIZED OPENLABEL TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS 65 YEARS OF AGE WITH PRIOR PNEUMOCOCCAL VACCINATION No dispute reported 06/30/2026 671679971
Principal investigator 1 PFIZER INC. $20,949.73 08/28/2019 Non-covered Recipient Entity
PMG Research of Wilmington LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINENAIVE ADULTS 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671684051
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,969.88 08/28/2019 Non-covered Recipient Entity
PMG RESEARCH INC
PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO AND NSAID CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP No dispute reported 06/30/2026 639750065
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $14,433.90 08/28/2019 Non-covered Recipient Entity
PMG RESEARCH INC
PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO AND NSAID CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP No dispute reported 06/30/2026 639750067
Principal investigator 1 Novo Nordisk AS $72.00 08/21/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4374 No dispute reported 06/30/2026 706703635
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,918.34 08/21/2019 Non-covered Recipient Entity
PMG RESEARCH INC
PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO AND NSAID CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP No dispute reported 06/30/2026 639750063
Principal investigator 1 PFIZER INC. $9,490.51 08/20/2019 Non-covered Recipient Entity
PMG Research of Wilmington LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF 2 DOSES COMPARED TO 3 DOSES OF CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671678547
Principal investigator 1 PFIZER INC. $12,527.54 08/20/2019 Non-covered Recipient Entity
PMG Research of Wilmington LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINENAIVE ADULTS 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671683909
Principal investigator 1 PFIZER INC. $1,179.90 08/17/2019 Non-covered Recipient Entity
PMG Research of Wilmington LLC
A PHASE 3 RANDOMIZED OPENLABEL TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS 65 YEARS OF AGE WITH PRIOR PNEUMOCOCCAL VACCINATION No dispute reported 06/30/2026 671680131
Principal investigator 1 Merck Sharp & Dohme Corporation $99.80 08/16/2019 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691353177
Principal investigator 1 SANOFI US SERVICES INC. $1,350.00 08/15/2019 Non-covered Recipient Entity
Pmg Research,Incorporation
A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin in Patients With Type 2 Diabetes Who Have Inadequate Glyc No dispute reported 06/30/2026 691610199
Principal investigator 1 PFIZER INC. $2,116.12 08/14/2019 Non-covered Recipient Entity
PMG RESEARCH INC
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671672451
Principal investigator 1 PFIZER INC. $7,983.60 08/14/2019 Non-covered Recipient Entity
PMG RESEARCH INC
A PHASE 2 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF TWO 3DOSE REGIMENS OF A CLOSTRIDIUM DIFFICILE VACCINE IN HEALTHY ADULTS AGED 65 TO 85 YEARS No dispute reported 06/30/2026 671678495
Principal investigator 1 GlaxoSmithKline, LLC. $3,365.10 08/13/2019 Non-covered Recipient Entity
PMG RESEARCH
RSV OA=ADJ-002 No dispute reported 06/30/2026 669973381
Principal investigator 1 GlaxoSmithKline, LLC. $2,821.50 08/13/2019 Non-covered Recipient Entity
PMG RESEARCH
RSV OA=ADJ-002 No dispute reported 06/30/2026 669975679
Principal investigator 1 Merck Sharp & Dohme Corporation $19,714.00 08/12/2019 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691449659
Principal investigator 1 Novo Nordisk AS $9.99 08/12/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4506 No dispute reported 06/30/2026 706703627
Principal investigator 1 Novo Nordisk AS $23.06 08/12/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4506 No dispute reported 06/30/2026 706703629
Principal investigator 1 Novo Nordisk AS $9.99 08/12/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4506 No dispute reported 06/30/2026 706703631
Principal investigator 1 Novo Nordisk AS $23.06 08/12/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4506 No dispute reported 06/30/2026 706703633
Principal investigator 1 Merck Sharp & Dohme Corporation $10.00 08/08/2019 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691449809
Principal investigator 1 Merck Sharp & Dohme Corporation $1,210.00 08/08/2019 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691449879
Principal investigator 1 Merck Sharp & Dohme Corporation $13.00 08/08/2019 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691449881
Principal investigator 1 Merck Sharp & Dohme Corporation $137.50 08/08/2019 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691449885
Principal investigator 1 Merck Sharp & Dohme Corporation $38.00 08/08/2019 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691451041
Principal investigator 1 Merck Sharp & Dohme Corporation $16.50 08/08/2019 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691451713
Principal investigator 1 Merck Sharp & Dohme Corporation $168.00 08/08/2019 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691451721
Principal investigator 1 Merck Sharp & Dohme Corporation $2,640.00 08/08/2019 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691451783
Principal investigator 1 Merck Sharp & Dohme Corporation $275.00 08/08/2019 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691451787
Principal investigator 1 Merck Sharp & Dohme Corporation $3.50 08/08/2019 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691451791
Principal investigator 1 Merck Sharp & Dohme Corporation $33.00 08/08/2019 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691451797
Principal investigator 1 Merck Sharp & Dohme Corporation $336.00 08/08/2019 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691451801
Principal investigator 1 Merck Sharp & Dohme Corporation $19.00 08/08/2019 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691451821
Principal investigator 1 Merck Sharp & Dohme Corporation $47.50 08/08/2019 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691452379
Principal investigator 1 Merck Sharp & Dohme Corporation $5.00 08/08/2019 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691452385
Principal investigator 1 Merck Sharp & Dohme Corporation $6.50 08/08/2019 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691452389
Principal investigator 1 Merck Sharp & Dohme Corporation $34.00 08/08/2019 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691452847
Principal investigator 1 Merck Sharp & Dohme Corporation $605.00 08/08/2019 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691452865
Principal investigator 1 Merck Sharp & Dohme Corporation $1,320.00 08/08/2019 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691453565
Principal investigator 1 Merck Sharp & Dohme Corporation $68.00 08/08/2019 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691462255
Principal investigator 1 Merck Sharp & Dohme Corporation $7.00 08/08/2019 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691462419
Principal investigator 1 Merck Sharp & Dohme Corporation $95.00 08/08/2019 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691462423
Principal investigator 1 Novo Nordisk AS $154,891.24 08/08/2019 Non-covered Recipient Entity
PMG RESEARCH INC
NN1250-4252 No dispute reported 06/30/2026 692464035
Principal investigator 1 Novo Nordisk AS $1,000.00 08/08/2019 Non-covered Recipient Entity
PMG RESEARCH INC
NN1250-4252 No dispute reported 06/30/2026 692464037
Principal investigator 1 Novo Nordisk AS $250.00 08/08/2019 Non-covered Recipient Entity
PMG RESEARCH INC
NN1250-4252 No dispute reported 06/30/2026 692464039
Principal investigator 1 Novo Nordisk AS $34.76 08/08/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4374 No dispute reported 06/30/2026 706703609
Principal investigator 1 Novo Nordisk AS $4.80 08/08/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4506 No dispute reported 06/30/2026 706703617
Principal investigator 1 Novo Nordisk AS $4.80 08/08/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4506 No dispute reported 06/30/2026 706703619
Principal investigator 1 GlaxoSmithKline, LLC. $1,861.20 08/07/2019 Non-covered Recipient Entity
PMG RESEARCH
RSV OA=ADJ-002 No dispute reported 06/30/2026 669961831
Principal investigator 1 GlaxoSmithKline, LLC. $2,196.00 08/07/2019 Non-covered Recipient Entity
PMG RESEARCH
RSV OA=ADJ-002 No dispute reported 06/30/2026 669962825
Principal investigator 1 GlaxoSmithKline, LLC. $3,909.60 08/07/2019 Non-covered Recipient Entity
PMG RESEARCH
RSV OA=ADJ-002 No dispute reported 06/30/2026 669964125
Principal investigator 1 GlaxoSmithKline, LLC. $3,219.30 08/07/2019 Non-covered Recipient Entity
PMG RESEARCH
RSV OA=ADJ-002 No dispute reported 06/30/2026 669964127
Principal investigator 1 GlaxoSmithKline, LLC. $26,415.00 08/07/2019 Non-covered Recipient Entity
PMG RESEARCH
RSV OA=ADJ-002 No dispute reported 06/30/2026 669965969
Principal investigator 1 GlaxoSmithKline, LLC. $3,178.80 08/07/2019 Non-covered Recipient Entity
PMG RESEARCH
RSV OA=ADJ-002 No dispute reported 06/30/2026 669968299
Principal investigator 1 Novo Nordisk AS $186.30 08/07/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4375 No dispute reported 06/30/2026 706703605
Principal investigator 1 Novo Nordisk AS $90.00 08/07/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 706704239
Principal investigator 1 Novo Nordisk AS $24.50 08/07/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 706704241
Principal investigator 1 Novo Nordisk AS $16.25 08/07/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 706704243
Principal investigator 1 Novo Nordisk AS $150.00 08/07/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 706704245
Principal investigator 1 Novo Nordisk AS $24.50 08/07/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 706704247
Principal investigator 1 Novo Nordisk AS $2.80 08/07/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 706704249
Principal investigator 1 Novo Nordisk AS $13.25 08/07/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 706704251
Principal investigator 1 Novo Nordisk AS $45.00 08/07/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 706704253
Principal investigator 1 Novo Nordisk AS $80.20 08/07/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 706704255
Principal investigator 1 Novo Nordisk AS $75.00 08/06/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 706704231
Principal investigator 1 PFIZER INC. $14,389.66 08/06/2019 Non-covered Recipient Entity
PMG Research of Wilmington LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF 2 DOSES COMPARED TO 3 DOSES OF CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671671495
Principal investigator 1 PFIZER INC. $25,278.10 08/06/2019 Non-covered Recipient Entity
PMG Research of Wilmington LLC
A PHASE 3 RANDOMIZED OPENLABEL TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS 65 YEARS OF AGE WITH PRIOR PNEUMOCOCCAL VACCINATION No dispute reported 06/30/2026 671680023
Principal investigator 1 PFIZER INC. $15,467.50 08/06/2019 Non-covered Recipient Entity
PMG Research of Wilmington LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINENAIVE ADULTS 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671683981
Principal investigator 1 SANOFI US SERVICES INC. $6,825.00 08/06/2019 Non-covered Recipient Entity
Pmg Research,Incorporation
A 26-week Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter, Phase 3 Study With a 78-week Extension Period to Evaluate the Efficacy and Bone Safety of Sotagliflozin in Patients No dispute reported 06/30/2026 691610151
Principal investigator 1 PFIZER INC. $2,513.68 08/03/2019 Non-covered Recipient Entity
PMG Research of Charlotte
PHASE III LOT CONSISTENCY TRIAL No dispute reported 06/30/2026 671669901
Principal investigator 1 Flexion Therapeutics, Inc. $21,072.54 08/01/2019 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of FX006 in Patients with Hip Osteoarthritis No dispute reported 06/30/2026 705979653
Principal investigator 1 Novo Nordisk AS $361.53 08/01/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4373 No dispute reported 06/30/2026 706703595
Principal investigator 1 SANOFI US SERVICES INC. $700.00 08/01/2019 Non-covered Recipient Entity
Pmg Research Of Winstonsalem
A 56-week, Multicenter, Double-blind, Placebo-controlled, Randomized Study to Evaluate the Efficacy and Safety of Efpeglenatide Once Weekly in Patients with Type 2 Diabetes Mellitus Inadequately Contr No dispute reported 06/30/2026 691577643
Principal investigator 1 SANOFI US SERVICES INC. $23,059.05 08/01/2019 Non-covered Recipient Entity
Pmg Research,Incorporation
A Randomized, Double-blind, Placebo-controlled, 3-arm, Parallel-group 52-week Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin in Patients With Type 2 Diabetes Mellitus and Moder No dispute reported 06/30/2026 691610145
Principal investigator 1 Novo Nordisk AS $2,500.00 07/31/2019 Non-covered Recipient Entity
PMG RESEARCH INC
NN9535-4506 No dispute reported 06/30/2026 692464029
Principal investigator 1 Novo Nordisk AS $500.00 07/31/2019 Non-covered Recipient Entity
PMG RESEARCH INC
NN9535-4506 No dispute reported 06/30/2026 692464031
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $16,770.19 07/31/2019 Non-covered Recipient Entity
PMG RESEARCH INC
PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO AND NSAID CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP No dispute reported 06/30/2026 639750061
Principal investigator 1 Novo Nordisk AS $14,479.03 07/30/2019 Non-covered Recipient Entity
PMG RESEARCH INC
NN9536-4375 No dispute reported 06/30/2026 692464135
Principal investigator 1 Novo Nordisk AS $11,697.82 07/30/2019 Non-covered Recipient Entity
PMG RESEARCH INC
EX9536-4388 No dispute reported 06/30/2026 692464143
Principal investigator 1 Novo Nordisk AS $8,747.63 07/30/2019 Non-covered Recipient Entity
PMG RESEARCH INC
NN9536-4374 No dispute reported 06/30/2026 692464149
Principal investigator 1 Novo Nordisk AS $22,625.88 07/30/2019 Non-covered Recipient Entity
PMG RESEARCH INC
NN9536-4373 No dispute reported 06/30/2026 692464159
Principal investigator 1 SANOFI US SERVICES INC. $2,025.00 07/29/2019 Non-covered Recipient Entity
Pmg Research,Incorporation
A 26-week Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter, Phase 3 Study With a 78-week Extension Period to Evaluate the Efficacy and Bone Safety of Sotagliflozin in Patients No dispute reported 06/30/2026 691610125
Principal investigator 1 SANOFI US SERVICES INC. $1,350.00 07/29/2019 Non-covered Recipient Entity
Pmg Research,Incorporation
A 26-week Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter, Phase 3 Study With a 78-week Extension Period to Evaluate the Efficacy and Bone Safety of Sotagliflozin in Patients No dispute reported 06/30/2026 691610132
Principal investigator 1 SANOFI US SERVICES INC. $425.00 07/26/2019 Non-covered Recipient Entity
Pmg Research Of Winstonsalem
A 56-week, Multicenter, Double-blind, Placebo-controlled, Randomized Study to Evaluate the Efficacy and Safety of Efpeglenatide Once Weekly in Patients with Type 2 Diabetes Mellitus Inadequately Contr No dispute reported 06/30/2026 691572512
Principal investigator 1 Novo Nordisk AS $24.99 07/25/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 706703585
Principal investigator 1 SANOFI US SERVICES INC. $3,098.00 07/22/2019 Non-covered Recipient Entity
Pmg Research,Incorporation
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin Added to Metformin in Patients With Type 2 Diabetes Mellitus Who No dispute reported 06/30/2026 691610103
Principal investigator 1 SANOFI US SERVICES INC. $2,007.80 07/22/2019 Non-covered Recipient Entity
Pmg Research,Incorporation
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin Added to Metformin in Patients With Type 2 Diabetes Mellitus Who No dispute reported 06/30/2026 691610109
Principal investigator 1 PFIZER INC. $24,688.15 07/20/2019 Non-covered Recipient Entity
PMG Research of Wilmington LLC
A PHASE 3 RANDOMIZED OPENLABEL TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS 65 YEARS OF AGE WITH PRIOR PNEUMOCOCCAL VACCINATION No dispute reported 06/30/2026 671679673
Principal investigator 1 PFIZER INC. $6,284.20 07/19/2019 Non-covered Recipient Entity
PMG Research of Charlotte
PHASE III LOT CONSISTENCY TRIAL No dispute reported 06/30/2026 671677315
Principal investigator 1 PFIZER INC. $3,862.83 07/18/2019 Non-covered Recipient Entity
PMG Research of Wilmington LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF 2 DOSES COMPARED TO 3 DOSES OF CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671672985
Principal investigator 1 Novo Nordisk AS $144.09 07/17/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 706704229
Principal investigator 1 PFIZER INC. $480.94 07/17/2019 Non-covered Recipient Entity
PMG RESEARCH INC
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671642583
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $31,886.58 07/17/2019 Non-covered Recipient Entity
PMG RESEARCH INC
PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO AND NSAID CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP No dispute reported 06/30/2026 639750059
Principal investigator 1 SANOFI US SERVICES INC. $1,500.00 07/15/2019 Non-covered Recipient Entity
Pmg Research Inc
Six-month, Randomized, Open-label, Parallel-group Comparison of SAR341402 to NovoLog/NovoRapid in Adult Patients With Diabetes Also Using Insulin Glargine, With a 6-month Safety Extension Period No dispute reported 06/30/2026 691591813
Principal investigator 1 PFIZER INC. $26,628.59 07/13/2019 Non-covered Recipient Entity
PMG Research of Wilmington LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINENAIVE ADULTS 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671683905
Principal investigator 1 Merck Sharp & Dohme Corporation $0.68 07/10/2019 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691449805
Principal investigator 1 Merck Sharp & Dohme Corporation $2.75 07/10/2019 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691449869
Principal investigator 1 Merck Sharp & Dohme Corporation $210.96 07/10/2019 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691449871
Principal investigator 1 Merck Sharp & Dohme Corporation $0.38 07/10/2019 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691450007
Principal investigator 1 Merck Sharp & Dohme Corporation $9,772.00 07/10/2019 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691451479
Principal investigator 1 Merck Sharp & Dohme Corporation $20.00 07/10/2019 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691452775
Principal investigator 1 PFIZER INC. $4,790.16 07/10/2019 Non-covered Recipient Entity
PMG RESEARCH INC
A PHASE 2 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF TWO 3DOSE REGIMENS OF A CLOSTRIDIUM DIFFICILE VACCINE IN HEALTHY ADULTS AGED 65 TO 85 YEARS No dispute reported 06/30/2026 671642555
Principal investigator 1 PFIZER INC. $12,324.78 07/10/2019 Non-covered Recipient Entity
PMG Research of Charlotte
PHASE III LOT CONSISTENCY TRIAL No dispute reported 06/30/2026 671669899
Principal investigator 1 PFIZER INC. $6,650.01 07/10/2019 Non-covered Recipient Entity
PMG Research of Wilmington LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF 2 DOSES COMPARED TO 3 DOSES OF CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671679181
Principal investigator 1 PFIZER INC. $589.95 07/10/2019 Non-covered Recipient Entity
PMG Research of Wilmington LLC
A PHASE 3 RANDOMIZED OPENLABEL TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS 65 YEARS OF AGE WITH PRIOR PNEUMOCOCCAL VACCINATION No dispute reported 06/30/2026 671680077
Principal investigator 1 PFIZER INC. $17,871.67 07/10/2019 Non-covered Recipient Entity
PMG Research of Wilmington LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINENAIVE ADULTS 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671683065
Principal investigator 1 SANOFI US SERVICES INC. $9,466.25 07/05/2019 Non-covered Recipient Entity
Pmg Research Of Winstonsalem
A 56-week, Multicenter, Double-blind, Placebo-controlled, Randomized Study to Evaluate the Efficacy and Safety of Efpeglenatide Once Weekly in Patients with Type 2 Diabetes Mellitus Inadequately Contr No dispute reported 06/30/2026 691575205
Principal investigator 1 SANOFI US SERVICES INC. $675.00 07/05/2019 Non-covered Recipient Entity
Pmg Research,Incorporation
A Randomized, Double-blind, Placebo-controlled, 3-arm, Parallel-group 52-week Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin in Patients With Type 2 Diabetes Mellitus and Moder No dispute reported 06/30/2026 691610051
Principal investigator 1 PFIZER INC. $721.41 07/02/2019 Non-covered Recipient Entity
PMG RESEARCH INC
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671642527
Principal investigator 1 Novo Nordisk AS $2.40 06/28/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 706704233
Principal investigator 1 Novo Nordisk AS $2.40 06/28/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 706704235
Principal investigator 1 Novo Nordisk AS $1.08 06/28/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 706704237
Principal investigator 1 Novo Nordisk AS $22.97 06/27/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 706703173
Principal investigator 1 PFIZER INC. $1,830.77 06/26/2019 Non-covered Recipient Entity
PMG RESEARCH INC
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671642581
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,237.50 06/26/2019 Non-covered Recipient Entity
PMG RESEARCH INC
PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO AND NSAID CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP No dispute reported 06/30/2026 639750057
Principal investigator 1 Novo Nordisk AS $5,957.74 06/25/2019 Non-covered Recipient Entity
PMG RESEARCH INC
NN9536-4374 No dispute reported 06/30/2026 692464093
Principal investigator 1 Novo Nordisk AS $12,403.22 06/25/2019 Non-covered Recipient Entity
PMG RESEARCH INC
NN9536-4375 No dispute reported 06/30/2026 692464101
Principal investigator 1 Novo Nordisk AS $13,214.88 06/25/2019 Non-covered Recipient Entity
PMG RESEARCH INC
EX9536-4388 No dispute reported 06/30/2026 692464111
Principal investigator 1 Novo Nordisk AS $15,891.84 06/25/2019 Non-covered Recipient Entity
PMG RESEARCH INC
NN9536-4373 No dispute reported 06/30/2026 692464117
Principal investigator 1 Novo Nordisk AS $198.00 06/25/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4374 No dispute reported 06/30/2026 706703547
Principal investigator 1 PFIZER INC. $18,953.20 06/25/2019 Non-covered Recipient Entity
PMG Research of Wilmington LLC
A PHASE 3 RANDOMIZED OPENLABEL TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS 65 YEARS OF AGE WITH PRIOR PNEUMOCOCCAL VACCINATION No dispute reported 06/30/2026 671635965
Principal investigator 1 PFIZER INC. $59,464.50 06/25/2019 Non-covered Recipient Entity
PMG Research of Wilmington LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINENAIVE ADULTS 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671683151
Principal investigator 1 PFIZER INC. $100.19 06/24/2019 Non-covered Recipient Entity
PMG Research of Wilmington LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINENAIVE ADULTS 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671683765
Principal investigator 1 PFIZER INC. $14,665.39 06/22/2019 Non-covered Recipient Entity
PMG Research of Wilmington LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF 2 DOSES COMPARED TO 3 DOSES OF CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671642551
Principal investigator 1 PFIZER INC. $4,129.65 06/22/2019 Non-covered Recipient Entity
PMG Research of Wilmington LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF 3 LOTS OF 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINENAIVE ADULTS 18 THROUGH 49 YEARS OF AGE No dispute reported 06/30/2026 671683153
Principal investigator 1 Novo Nordisk AS $384.10 06/20/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4375 No dispute reported 06/30/2026 706703541
Principal investigator 1 PFIZER INC. $17,031.56 06/20/2019 Non-covered Recipient Entity
PMG Research of Charlotte
PHASE III LOT CONSISTENCY TRIAL No dispute reported 06/30/2026 671642529
Principal investigator 1 SANOFI US SERVICES INC. $23,700.00 06/20/2019 Non-covered Recipient Entity
Pmg Research,Incorporation
A 26-week Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter, Phase 3 Study With a 78-week Extension Period to Evaluate the Efficacy and Bone Safety of Sotagliflozin in Patients No dispute reported 06/30/2026 691610031
Principal investigator 1 Novo Nordisk AS $36.00 06/19/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 706704209
Principal investigator 1 Novo Nordisk AS $9.00 06/19/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 706704211
Principal investigator 1 Novo Nordisk AS $6.50 06/19/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 706704213
Principal investigator 1 Novo Nordisk AS $60.00 06/19/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 706704215
Principal investigator 1 Novo Nordisk AS $9.00 06/19/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 706704217
Principal investigator 1 Novo Nordisk AS $49.98 06/19/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 706704219
Principal investigator 1 Novo Nordisk AS $5.30 06/19/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 706704221
Principal investigator 1 Novo Nordisk AS $4.99 06/19/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 706704223
Principal investigator 1 Novo Nordisk AS $5.36 06/19/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 706704225
Principal investigator 1 Novo Nordisk AS $3.05 06/19/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 706704227
Principal investigator 1 PFIZER INC. $9,369.55 06/19/2019 Non-covered Recipient Entity
PMG RESEARCH INC
A PHASE 12 RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY ADULTS 50 THROUGH 85 YEARS OF AGE No dispute reported 06/30/2026 671679969
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $84,266.97 06/19/2019 Non-covered Recipient Entity
PMG RESEARCH INC
PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO AND NSAID CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP No dispute reported 06/30/2026 639750055
Principal investigator 1 Merck Sharp & Dohme Corporation $11,667.00 06/14/2019 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691359109
Principal investigator 1 Novo Nordisk AS $1.14 06/12/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4506 No dispute reported 06/30/2026 706703491
Principal investigator 1 Novo Nordisk AS $11.38 06/12/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4506 No dispute reported 06/30/2026 706703493
Principal investigator 1 Novo Nordisk AS $9.98 06/12/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4506 No dispute reported 06/30/2026 706703495
Principal investigator 1 Novo Nordisk AS $5.30 06/12/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4506 No dispute reported 06/30/2026 706703497
Principal investigator 1 Novo Nordisk AS $49.98 06/12/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4506 No dispute reported 06/30/2026 706703499
Principal investigator 1 Novo Nordisk AS $9.00 06/12/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4506 No dispute reported 06/30/2026 706703501
Principal investigator 1 Novo Nordisk AS $60.00 06/12/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4506 No dispute reported 06/30/2026 706703503
Principal investigator 1 Novo Nordisk AS $6.50 06/12/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4506 No dispute reported 06/30/2026 706703505
Principal investigator 1 Novo Nordisk AS $9.80 06/12/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4506 No dispute reported 06/30/2026 706703507
Principal investigator 1 Novo Nordisk AS $36.00 06/12/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4506 No dispute reported 06/30/2026 706703509
Principal investigator 1 PFIZER INC. $400.76 06/11/2019 Non-covered Recipient Entity
PMG Research of Wilmington LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINENAIVE ADULTS 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671683681
Principal investigator 1 Merck Sharp & Dohme Corporation $3.50 06/10/2019 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691389625
Principal investigator 1 Merck Sharp & Dohme Corporation $34.00 06/10/2019 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691389703
Principal investigator 1 Merck Sharp & Dohme Corporation $4.04 06/10/2019 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691389707
Principal investigator 1 Merck Sharp & Dohme Corporation $6.50 06/10/2019 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691389759
Principal investigator 1 Merck Sharp & Dohme Corporation $605.00 06/10/2019 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691389767
Principal investigator 1 Merck Sharp & Dohme Corporation $47.50 06/10/2019 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691390185
Principal investigator 1 Merck Sharp & Dohme Corporation $1.20 06/10/2019 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691390759
Principal investigator 1 Merck Sharp & Dohme Corporation $12.10 06/10/2019 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691390763
Principal investigator 1 Merck Sharp & Dohme Corporation $1,320.00 06/10/2019 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691390787
Principal investigator 1 Merck Sharp & Dohme Corporation $137.50 06/10/2019 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691391193
Principal investigator 1 Merck Sharp & Dohme Corporation $16.50 06/10/2019 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691391721
Principal investigator 1 Merck Sharp & Dohme Corporation $168.00 06/10/2019 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691391727
Principal investigator 1 Merck Sharp & Dohme Corporation $19.00 06/10/2019 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691391731
Principal investigator 1 Merck Sharp & Dohme Corporation $5.00 06/10/2019 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691396283
Principal investigator 1 Merck Sharp & Dohme Corporation $4.84 06/10/2019 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691396775
Principal investigator 1 Merck Sharp & Dohme Corporation $14.20 06/10/2019 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691397915
Principal investigator 1 Novo Nordisk AS $63.52 06/10/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4506 No dispute reported 06/30/2026 706703175
Principal investigator 1 PFIZER INC. $21,422.90 06/06/2019 Non-covered Recipient Entity
PMG Research of Wilmington LLC
A PHASE 3 RANDOMIZED OPENLABEL TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS 65 YEARS OF AGE WITH PRIOR PNEUMOCOCCAL VACCINATION No dispute reported 06/30/2026 671635851
Principal investigator 1 PFIZER INC. $62,205.18 06/05/2019 Non-covered Recipient Entity
PMG Research of Wilmington LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINENAIVE ADULTS 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671683069
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $18,279.00 06/05/2019 Non-covered Recipient Entity
PMG RESEARCH INC
PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO AND NSAID CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP No dispute reported 06/30/2026 639750053
Principal investigator 1 PFIZER INC. $701.33 06/03/2019 Non-covered Recipient Entity
PMG Research of Wilmington LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINENAIVE ADULTS 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671683685
Principal investigator 1 PFIZER INC. $15,531.10 06/01/2019 Non-covered Recipient Entity
PMG Research of Charlotte
PHASE III LOT CONSISTENCY TRIAL No dispute reported 06/30/2026 671642553
Principal investigator 1 PFIZER INC. $689.85 06/01/2019 Non-covered Recipient Entity
PMG Research of Hickory LLC
A PHASE 12 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING FIRSTINHUMAN STUDY TO DESCRIBE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A RESPIRATORY SYNCYTIAL VIRUS RSV VACCINE IN HEALTHY ADULTS No dispute reported 06/30/2026 671642579
Principal investigator 1 PFIZER INC. $6,489.45 06/01/2019 Non-covered Recipient Entity
PMG Research of Wilmington LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF 3 LOTS OF 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINENAIVE ADULTS 18 THROUGH 49 YEARS OF AGE No dispute reported 06/30/2026 671683067
Principal investigator 1 PFIZER INC. $6,730.08 05/31/2019 Non-covered Recipient Entity
PMG Research of Wilmington LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF 2 DOSES COMPARED TO 3 DOSES OF CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671625905
Principal investigator 1 SANOFI US SERVICES INC. $2,102.80 05/30/2019 Non-covered Recipient Entity
Pmg Research,Incorporation
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin Added to Metformin in Patients With Type 2 Diabetes Mellitus Who No dispute reported 06/30/2026 691610017
Principal investigator 1 SANOFI US SERVICES INC. $24,359.75 05/29/2019 Non-covered Recipient Entity
Pmg Research,Incorporation DBA Pmg Research Of Salisbury,LLC
A 56-week, Multicenter, Double-blind, Placebo-controlled, Randomized Study to Evaluate the Efficacy and Safety of Efpeglenatide Once Weekly in Patients with Type 2 Diabetes Mellitus Inadequately Contr No dispute reported 06/30/2026 691555029
Principal investigator 1 Novo Nordisk AS $8,756.26 05/28/2019 Non-covered Recipient Entity
PMG RESEARCH INC
NN9536-4374 No dispute reported 06/30/2026 692464091
Principal investigator 1 Novo Nordisk AS $23,154.16 05/28/2019 Non-covered Recipient Entity
PMG RESEARCH INC
NN9536-4375 No dispute reported 06/30/2026 692464099
Principal investigator 1 Novo Nordisk AS $15,106.58 05/28/2019 Non-covered Recipient Entity
PMG RESEARCH INC
EX9536-4388 No dispute reported 06/30/2026 692464107
Principal investigator 1 Novo Nordisk AS $839.87 05/28/2019 Non-covered Recipient Entity
PMG RESEARCH INC
EX9536-4388 No dispute reported 06/30/2026 692464109
Principal investigator 1 Novo Nordisk AS $19,134.31 05/28/2019 Non-covered Recipient Entity
PMG RESEARCH INC
NN9536-4373 No dispute reported 06/30/2026 692464115
Principal investigator 1 Novo Nordisk AS $607.00 05/24/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 706704187
Principal investigator 1 PFIZER INC. $13,532.95 05/24/2019 Non-covered Recipient Entity
PMG Research of Wilmington LLC
A PHASE 3 RANDOMIZED OPENLABEL TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS 65 YEARS OF AGE WITH PRIOR PNEUMOCOCCAL VACCINATION No dispute reported 06/30/2026 671643455
Principal investigator 1 PFIZER INC. $41,296.50 05/24/2019 Non-covered Recipient Entity
PMG Research of Wilmington LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF 3 LOTS OF 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINENAIVE ADULTS 18 THROUGH 49 YEARS OF AGE No dispute reported 06/30/2026 671683241
Principal investigator 1 PFIZER INC. $55,021.79 05/24/2019 Non-covered Recipient Entity
PMG Research of Wilmington LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINENAIVE ADULTS 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671683243
Principal investigator 1 Novo Nordisk AS $191.97 05/23/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4373 No dispute reported 06/30/2026 706703457
Principal investigator 1 PFIZER INC. $150.00 05/22/2019 Non-covered Recipient Entity
PMG RESEARCH INC
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671625031
Principal investigator 1 PFIZER INC. $195.00 05/22/2019 Non-covered Recipient Entity
PMG RESEARCH INC
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671625143
Principal investigator 1 PFIZER INC. $1,125.00 05/22/2019 Non-covered Recipient Entity
PMG RESEARCH INC
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671625415
Principal investigator 1 PFIZER INC. $15,432.20 05/22/2019 Non-covered Recipient Entity
PMG RESEARCH INC
A PHASE 12 RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY ADULTS 50 THROUGH 85 YEARS OF AGE No dispute reported 06/30/2026 671679849
Principal investigator 1 PFIZER INC. $400.76 05/22/2019 Non-covered Recipient Entity
PMG Research of Wilmington LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINENAIVE ADULTS 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671683683
Principal investigator 1 SANOFI US SERVICES INC. $700.00 05/22/2019 Non-covered Recipient Entity
Pmg Research,Incorporation DBA Pmg Research Of Salisbury,LLC
A 56-week, Multicenter, Double-blind, Placebo-controlled, Randomized Study to Evaluate the Efficacy and Safety of Efpeglenatide Once Weekly in Patients with Type 2 Diabetes Mellitus Inadequately Contr No dispute reported 06/30/2026 691554174
Principal investigator 1 PFIZER INC. $6,296.46 05/21/2019 Non-covered Recipient Entity
PMG Research of Charlotte
PHASE III LOT CONSISTENCY TRIAL No dispute reported 06/30/2026 671625393
Principal investigator 1 Merck Sharp & Dohme Corporation $7,744.00 05/20/2019 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691318285
Principal investigator 1 PFIZER INC. $689.85 05/18/2019 Non-covered Recipient Entity
PMG Research of Hickory LLC
A PHASE 12 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING FIRSTINHUMAN STUDY TO DESCRIBE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A RESPIRATORY SYNCYTIAL VIRUS RSV VACCINE IN HEALTHY ADULTS No dispute reported 06/30/2026 671632465
Principal investigator 1 Novo Nordisk AS $153.41 05/16/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4375 No dispute reported 06/30/2026 706703439
Principal investigator 1 Novo Nordisk AS $153.41 05/16/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4375 No dispute reported 06/30/2026 706703441
Principal investigator 1 PFIZER INC. $6,200.00 05/16/2019 Non-covered Recipient Entity
PMG Research of Wilmington LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF 2 DOSES COMPARED TO 3 DOSES OF CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671625005
Principal investigator 1 SANOFI US SERVICES INC. $14,850.00 05/16/2019 Non-covered Recipient Entity
Pmg Research,Incorporation
A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin in Patients With Type 2 Diabetes Who Have Inadequate Glyc No dispute reported 06/30/2026 691609969
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $24,803.24 05/15/2019 Non-covered Recipient Entity
PMG RESEARCH INC
PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO AND NSAID CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP No dispute reported 06/30/2026 639750051
Principal investigator 1 PFIZER INC. $14,979.64 05/14/2019 Non-covered Recipient Entity
PMG Research of Charlotte
PHASE III LOT CONSISTENCY TRIAL No dispute reported 06/30/2026 671625185
Principal investigator 1 PFIZER INC. $500.95 05/14/2019 Non-covered Recipient Entity
PMG Research of Wilmington LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINENAIVE ADULTS 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671683609
Principal investigator 1 Merck Sharp & Dohme Corporation $8,928.00 05/13/2019 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691318289
Principal investigator 1 SANOFI US SERVICES INC. $8,363.00 05/13/2019 Non-covered Recipient Entity
Pmg Research,Incorporation
A 26-week Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter, Phase 3 Study With a 78-week Extension Period to Evaluate the Efficacy and Bone Safety of Sotagliflozin in Patients No dispute reported 06/30/2026 691609953
Principal investigator 1 Merck Sharp & Dohme Corporation $325.00 05/10/2019 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691317007
Principal investigator 1 PFIZER INC. $6,374.51 05/10/2019 Non-covered Recipient Entity
PMG Research of Hickory LLC
A PHASE 12 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING FIRSTINHUMAN STUDY TO DESCRIBE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A RESPIRATORY SYNCYTIAL VIRUS RSV VACCINE IN HEALTHY ADULTS No dispute reported 06/30/2026 671632327
Principal investigator 1 PFIZER INC. $1,349.83 05/08/2019 Non-covered Recipient Entity
PMG RESEARCH INC
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671628065
Principal investigator 1 PFIZER INC. $95,194.95 05/08/2019 Non-covered Recipient Entity
PMG Research of Wilmington LLC
A PHASE 3 RANDOMIZED OPENLABEL TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS 65 YEARS OF AGE WITH PRIOR PNEUMOCOCCAL VACCINATION No dispute reported 06/30/2026 671643669
Principal investigator 1 PFIZER INC. $52,411.99 05/08/2019 Non-covered Recipient Entity
PMG Research of Wilmington LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINENAIVE ADULTS 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671683155
Principal investigator 1 Novo Nordisk AS $49.98 05/07/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 706703419
Principal investigator 1 Novo Nordisk AS $72.00 05/06/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4374 No dispute reported 06/30/2026 706703413
Principal investigator 1 PFIZER INC. $601.14 05/06/2019 Non-covered Recipient Entity
PMG Research of Wilmington LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINENAIVE ADULTS 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671683761
Principal investigator 1 PFIZER INC. $200.38 05/06/2019 Non-covered Recipient Entity
PMG Research of Wilmington LLC
A PHASE 3 RANDOMIZED OPENLABEL TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS 65 YEARS OF AGE WITH PRIOR PNEUMOCOCCAL VACCINATION No dispute reported 06/30/2026 671684253
Principal investigator 1 SANOFI US SERVICES INC. $28,631.50 05/06/2019 Non-covered Recipient Entity
Pmg Research,Incorporation
A 26-week Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter, Phase 3 Study With a 78-week Extension Period to Evaluate the Efficacy and Bone Safety of Sotagliflozin in Patients No dispute reported 06/30/2026 691609931
Principal investigator 1 PFIZER INC. $26,792.43 05/04/2019 Non-covered Recipient Entity
PMG Research of Wilmington LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF 3 LOTS OF 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINENAIVE ADULTS 18 THROUGH 49 YEARS OF AGE No dispute reported 06/30/2026 671683395
Principal investigator 1 Novo Nordisk AS $24.99 04/29/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 706703411
Principal investigator 1 Novo Nordisk AS $8,698.50 04/25/2019 Non-covered Recipient Entity
PMG RESEARCH INC
NN9536-4374 No dispute reported 06/30/2026 692464089
Principal investigator 1 Novo Nordisk AS $20,811.90 04/25/2019 Non-covered Recipient Entity
PMG RESEARCH INC
NN9536-4375 No dispute reported 06/30/2026 692464095
Principal investigator 1 Novo Nordisk AS $187.50 04/25/2019 Non-covered Recipient Entity
PMG RESEARCH INC
NN9536-4375 No dispute reported 06/30/2026 692464097
Principal investigator 1 Novo Nordisk AS $21,485.95 04/25/2019 Non-covered Recipient Entity
PMG RESEARCH INC
NN9536-4373 No dispute reported 06/30/2026 692464103
Principal investigator 1 Novo Nordisk AS $7,827.79 04/25/2019 Non-covered Recipient Entity
PMG RESEARCH INC
EX9536-4388 No dispute reported 06/30/2026 692464105
Principal investigator 1 Novo Nordisk AS $187.50 04/25/2019 Non-covered Recipient Entity
PMG RESEARCH INC
NN9536-4373 No dispute reported 06/30/2026 692464113
Principal investigator 1 PFIZER INC. $901.71 04/25/2019 Non-covered Recipient Entity
PMG Research of Wilmington LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINENAIVE ADULTS 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671683611
Principal investigator 1 SANOFI US SERVICES INC. $128.00 04/25/2019 Non-covered Recipient Entity
Pmg Research,Incorporation
A 26-week Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter, Phase 3 Study With a 78-week Extension Period to Evaluate the Efficacy and Bone Safety of Sotagliflozin in Patients No dispute reported 06/30/2026 691611677
Principal investigator 1 PFIZER INC. $289,721.63 04/24/2019 Non-covered Recipient Entity
PMG Research of Wilmington LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINENAIVE ADULTS 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671683317
Principal investigator 1 Novo Nordisk AS $147.29 04/23/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4374 No dispute reported 06/30/2026 706703397
Principal investigator 1 PFIZER INC. $20,737.86 04/23/2019 Non-covered Recipient Entity
PMG Research of Hickory LLC
A PHASE 12 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING FIRSTINHUMAN STUDY TO DESCRIBE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A RESPIRATORY SYNCYTIAL VIRUS RSV VACCINE IN HEALTHY ADULTS No dispute reported 06/30/2026 671632467
Principal investigator 1 SANOFI US SERVICES INC. $8,623.20 04/23/2019 Non-covered Recipient Entity
Pmg Research,Incorporation
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin Added to Metformin in Patients With Type 2 Diabetes Mellitus Who No dispute reported 06/30/2026 691611663
Principal investigator 1 PFIZER INC. $9,888.06 04/20/2019 Non-covered Recipient Entity
PMG Research of Charlotte
PHASE III LOT CONSISTENCY TRIAL No dispute reported 06/30/2026 671628127
Principal investigator 1 PFIZER INC. $129,518.55 04/20/2019 Non-covered Recipient Entity
PMG Research of Wilmington LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF 3 LOTS OF 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINENAIVE ADULTS 18 THROUGH 49 YEARS OF AGE No dispute reported 06/30/2026 671683239
Principal investigator 1 SANOFI US SERVICES INC. $675.00 04/18/2019 Non-covered Recipient Entity
Pmg Research,Incorporation
A Randomized, Double-blind, Placebo-controlled, 3-arm, Parallel-group 52-week Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin in Patients With Type 2 Diabetes Mellitus and Moder No dispute reported 06/30/2026 691611587
Principal investigator 1 SANOFI US SERVICES INC. $6,533.00 04/18/2019 Non-covered Recipient Entity
Pmg Research,Incorporation
A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin in Patients With Type 2 Diabetes Who Have Inadequate Glyc No dispute reported 06/30/2026 691611647
Principal investigator 1 SANOFI US SERVICES INC. $1,350.00 04/18/2019 Non-covered Recipient Entity
Pmg Research,Incorporation
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin Added to Metformin in Patients With Type 2 Diabetes Mellitus Who No dispute reported 06/30/2026 691611653
Principal investigator 1 PFIZER INC. $6,062.65 04/17/2019 Non-covered Recipient Entity
PMG RESEARCH INC
A PHASE 12 RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY ADULTS 50 THROUGH 85 YEARS OF AGE No dispute reported 06/30/2026 671679847
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $55,917.95 04/17/2019 Non-covered Recipient Entity
PMG RESEARCH INC
PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO AND NSAID CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP No dispute reported 06/30/2026 639750049
Principal investigator 1 PFIZER INC. $300.57 04/15/2019 Non-covered Recipient Entity
PMG Research of Wilmington LLC
A PHASE 3 RANDOMIZED OPENLABEL TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS 65 YEARS OF AGE WITH PRIOR PNEUMOCOCCAL VACCINATION No dispute reported 06/30/2026 671684449
Principal investigator 1 Merck Sharp & Dohme Corporation $24,072.00 04/12/2019 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691317001
Principal investigator 1 PFIZER INC. $5,489.12 04/11/2019 Non-covered Recipient Entity
PMG Research of Charlotte
PHASE III LOT CONSISTENCY TRIAL No dispute reported 06/30/2026 671625301
Principal investigator 1 Novo Nordisk AS $24.99 04/10/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 706703373
Principal investigator 1 PFIZER INC. $6,200.00 04/10/2019 Non-covered Recipient Entity
PMG Research of Wilmington LLC
A PHASE 3 RANDOMIZED OPENLABEL TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS 65 YEARS OF AGE WITH PRIOR PNEUMOCOCCAL VACCINATION No dispute reported 06/30/2026 671642577
Principal investigator 1 PFIZER INC. $145,997.80 04/10/2019 Non-covered Recipient Entity
PMG Research of Wilmington LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF 3 LOTS OF 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINENAIVE ADULTS 18 THROUGH 49 YEARS OF AGE No dispute reported 06/30/2026 671683319
Principal investigator 1 PFIZER INC. $300.57 04/10/2019 Non-covered Recipient Entity
PMG Research of Wilmington LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINENAIVE ADULTS 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671683763
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,710.00 04/10/2019 Non-covered Recipient Entity
PMG RESEARCH INC
PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO AND NSAID CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP No dispute reported 06/30/2026 639750045
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $325.00 04/10/2019 Non-covered Recipient Entity
PMG RESEARCH INC
PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO AND NSAID CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP No dispute reported 06/30/2026 639750047
Principal investigator 1 PFIZER INC. $6,117.54 04/09/2019 Non-covered Recipient Entity
PMG Research of Charlotte
PHASE III LOT CONSISTENCY TRIAL No dispute reported 06/30/2026 671628191
Principal investigator 1 PFIZER INC. $1,256.84 04/09/2019 Non-covered Recipient Entity
PMG Research of Hickory LLC
A PHASE 12 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING FIRSTINHUMAN STUDY TO DESCRIBE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A RESPIRATORY SYNCYTIAL VIRUS RSV VACCINE IN HEALTHY ADULTS No dispute reported 06/30/2026 671632391
Principal investigator 1 PFIZER INC. $200.38 04/09/2019 Non-covered Recipient Entity
PMG Research of Wilmington LLC
A PHASE 3 RANDOMIZED OPENLABEL TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS 65 YEARS OF AGE WITH PRIOR PNEUMOCOCCAL VACCINATION No dispute reported 06/30/2026 671684409
Principal investigator 1 Merck Sharp & Dohme Corporation $3.50 04/08/2019 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691389619
Principal investigator 1 Merck Sharp & Dohme Corporation $34.00 04/08/2019 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691389628
Principal investigator 1 Merck Sharp & Dohme Corporation $6.50 04/08/2019 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691389755
Principal investigator 1 Merck Sharp & Dohme Corporation $605.00 04/08/2019 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691389763
Principal investigator 1 Merck Sharp & Dohme Corporation $99.00 04/08/2019 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691389997
Principal investigator 1 Merck Sharp & Dohme Corporation $47.50 04/08/2019 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691390181
Principal investigator 1 Merck Sharp & Dohme Corporation $48.40 04/08/2019 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691390189
Principal investigator 1 Merck Sharp & Dohme Corporation $297.00 04/08/2019 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691390241
Principal investigator 1 Merck Sharp & Dohme Corporation $5.00 04/08/2019 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691390267
Principal investigator 1 Merck Sharp & Dohme Corporation $137.50 04/08/2019 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691391189
Principal investigator 1 Merck Sharp & Dohme Corporation $14.08 04/08/2019 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691391197
Principal investigator 1 Merck Sharp & Dohme Corporation $16.50 04/08/2019 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691391199
Principal investigator 1 Merck Sharp & Dohme Corporation $168.00 04/08/2019 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691391723
Principal investigator 1 Merck Sharp & Dohme Corporation $1,320.00 04/08/2019 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691397459
Principal investigator 1 Merck Sharp & Dohme Corporation $19.00 04/08/2019 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691397921
Principal investigator 1 SANOFI US SERVICES INC. $113.00 04/08/2019 Non-covered Recipient Entity
Pmg Research,Incorporation
A 26-week Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter, Phase 3 Study With a 78-week Extension Period to Evaluate the Efficacy and Bone Safety of Sotagliflozin in Patients No dispute reported 06/30/2026 691611579
Principal investigator 1 SANOFI US SERVICES INC. $6,256.50 04/03/2019 Non-covered Recipient Entity
Pmg Research,Incorporation DBA Pmg Research Of Salisbury,LLC
A 56-week, Multicenter, Double-blind, Placebo-controlled, Randomized Study to Evaluate the Efficacy and Safety of Efpeglenatide Once Weekly in Patients with Type 2 Diabetes Mellitus Inadequately Contr No dispute reported 06/30/2026 691555519
Principal investigator 1 PFIZER INC. $100.19 04/01/2019 Non-covered Recipient Entity
PMG Research of Wilmington LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINENAIVE ADULTS 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671683831
Principal investigator 1 Novo Nordisk AS $98,058.24 03/29/2019 Non-covered Recipient Entity
PMG RESEARCH INC
NN8022-4272 No dispute reported 06/30/2026 692464021
Principal investigator 1 PFIZER INC. $375.00 03/27/2019 Non-covered Recipient Entity
PMG RESEARCH INC
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671625781
Principal investigator 1 PFIZER INC. $65.00 03/27/2019 Non-covered Recipient Entity
PMG RESEARCH INC
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671627459
Principal investigator 1 PFIZER INC. $705.38 03/27/2019 Non-covered Recipient Entity
PMG RESEARCH INC
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671627495
Principal investigator 1 PFIZER INC. $50.00 03/27/2019 Non-covered Recipient Entity
PMG RESEARCH INC
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671628063
Principal investigator 1 Novo Nordisk AS $750.00 03/26/2019 Non-covered Recipient Entity
PMG RESEARCH INC
NN8022-4272 No dispute reported 06/30/2026 692464017
Principal investigator 1 Novo Nordisk AS $250.00 03/26/2019 Non-covered Recipient Entity
PMG RESEARCH INC
NN8022-4272 No dispute reported 06/30/2026 692464019
Principal investigator 1 Novo Nordisk AS $8,252.63 03/26/2019 Non-covered Recipient Entity
PMG RESEARCH INC
NN9536-4374 No dispute reported 06/30/2026 692464063
Principal investigator 1 Novo Nordisk AS $235.00 03/26/2019 Non-covered Recipient Entity
PMG RESEARCH INC
NN9536-4374 No dispute reported 06/30/2026 692464065
Principal investigator 1 Novo Nordisk AS $33,195.63 03/26/2019 Non-covered Recipient Entity
PMG RESEARCH INC
NN9536-4375 No dispute reported 06/30/2026 692464071
Principal investigator 1 Novo Nordisk AS $27,397.25 03/26/2019 Non-covered Recipient Entity
PMG RESEARCH INC
NN9536-4373 No dispute reported 06/30/2026 692464079
Principal investigator 1 Novo Nordisk AS $22,054.59 03/26/2019 Non-covered Recipient Entity
PMG RESEARCH INC
EX9536-4388 No dispute reported 06/30/2026 692464085
Principal investigator 1 Novo Nordisk AS $961.89 03/26/2019 Non-covered Recipient Entity
PMG RESEARCH INC
EX9536-4388 No dispute reported 06/30/2026 692464087
Principal investigator 1 PFIZER INC. $3,454.96 03/26/2019 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON LLC
A PHASE 12 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING FIRSTINHUMAN STUDY TO DESCRIBE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A RESPIRATORY SYNCYTIAL VIRUS RSV VACCINE IN HEALTHY ADULTS No dispute reported 06/30/2026 671632437
Principal investigator 1 SANOFI US SERVICES INC. $6,900.00 03/26/2019 Non-covered Recipient Entity
Pmg Research,Incorporation
A 26-week Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter, Phase 3 Study With a 78-week Extension Period to Evaluate the Efficacy and Bone Safety of Sotagliflozin in Patients No dispute reported 06/30/2026 691611555
Principal investigator 1 Novo Nordisk AS $24.99 03/22/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 706703359
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $630.00 03/20/2019 Non-covered Recipient Entity
PMG RESEARCH INC
PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO AND NSAID CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP No dispute reported 06/30/2026 639750041
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $62,939.02 03/20/2019 Non-covered Recipient Entity
PMG RESEARCH INC
PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO AND NSAID CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP No dispute reported 06/30/2026 639750043
Principal investigator 1 PFIZER INC. $300.57 03/18/2019 Non-covered Recipient Entity
PMG Research of Wilmington LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINENAIVE ADULTS 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671683465
Principal investigator 1 Merck Sharp & Dohme Corporation $23,022.00 03/13/2019 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691317793
Principal investigator 1 PFIZER INC. $195.00 03/13/2019 Non-covered Recipient Entity
PMG RESEARCH INC
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671627393
Principal investigator 1 PFIZER INC. $1,125.00 03/13/2019 Non-covered Recipient Entity
PMG RESEARCH INC
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671627463
Principal investigator 1 PFIZER INC. $3,200.00 03/13/2019 Non-covered Recipient Entity
PMG RESEARCH INC
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671628029
Principal investigator 1 PFIZER INC. $2,055.21 03/13/2019 Non-covered Recipient Entity
PMG RESEARCH INC
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671628031
Principal investigator 1 PFIZER INC. $150.00 03/13/2019 Non-covered Recipient Entity
PMG RESEARCH INC
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671628095
Principal investigator 1 PFIZER INC. $200.38 03/11/2019 Non-covered Recipient Entity
PMG Research of Wilmington LLC
A PHASE 3 RANDOMIZED OPENLABEL TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS 65 YEARS OF AGE WITH PRIOR PNEUMOCOCCAL VACCINATION No dispute reported 06/30/2026 671626017
Principal investigator 1 SANOFI US SERVICES INC. $8,556.50 03/08/2019 Non-covered Recipient Entity
Pmg Research Of Wilmington,LLC
A 56-week, Multicenter, Double-blind, Placebo-controlled, Randomized Study to Evaluate the Efficacy and Safety of Efpeglenatide Once Weekly in Patients with Type 2 Diabetes Mellitus Inadequately Contr No dispute reported 06/30/2026 691549917
Principal investigator 1 PFIZER INC. $400.76 03/07/2019 Non-covered Recipient Entity
PMG Research of Wilmington LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINENAIVE ADULTS 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671683467
Principal investigator 1 Novo Nordisk AS $24.99 03/05/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 706703335
Principal investigator 1 PFIZER INC. $200.38 03/05/2019 Non-covered Recipient Entity
PMG Research of Wilmington LLC
A PHASE 3 RANDOMIZED OPENLABEL TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS 65 YEARS OF AGE WITH PRIOR PNEUMOCOCCAL VACCINATION No dispute reported 06/30/2026 671625697
Principal investigator 1 PFIZER INC. $5,099.10 03/05/2019 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON LLC
A PHASE 12 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING FIRSTINHUMAN STUDY TO DESCRIBE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A RESPIRATORY SYNCYTIAL VIRUS RSV VACCINE IN HEALTHY ADULTS No dispute reported 06/30/2026 671632439
Principal investigator 1 Novo Nordisk AS $263.23 03/04/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4374 No dispute reported 06/30/2026 706703329
Principal investigator 1 PFIZER INC. $750.00 03/04/2019 Non-covered Recipient Entity
PMG RESEARCH INC
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671627391
Principal investigator 1 PFIZER INC. $130.00 03/04/2019 Non-covered Recipient Entity
PMG RESEARCH INC
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671627461
Principal investigator 1 PFIZER INC. $150.00 03/04/2019 Non-covered Recipient Entity
PMG RESEARCH INC
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671628061
Principal investigator 1 PFIZER INC. $3,244.73 03/04/2019 Non-covered Recipient Entity
PMG RESEARCH INC
A PHASE 2 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF TWO 3DOSE REGIMENS OF A CLOSTRIDIUM DIFFICILE VACCINE IN HEALTHY ADULTS AGED 65 TO 85 YEARS No dispute reported 06/30/2026 671628097
Principal investigator 1 SANOFI US SERVICES INC. $95.00 02/28/2019 Non-covered Recipient Entity
Pmg Research,Incorporation
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin Added to Metformin in Patients With Type 2 Diabetes Mellitus Who No dispute reported 06/30/2026 691611489
Principal investigator 1 SANOFI US SERVICES INC. $1,400.00 02/27/2019 Non-covered Recipient Entity
Pmg Research Of Wilmington,LLC
A 56-week, Multicenter, Double-blind, Placebo-controlled, Randomized Study to Evaluate the Efficacy and Safety of Efpeglenatide Once Weekly in Patients with Type 2 Diabetes Mellitus Inadequately Contr No dispute reported 06/30/2026 691549525
Principal investigator 1 Eisai Inc. $2,705.00 02/26/2019 Non-covered Recipient Entity
PMG RESEARCH OF SALISBURY LLC
A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors No dispute reported 06/30/2026 702522289
Principal investigator 1 Novo Nordisk AS $10,000.00 02/26/2019 Non-covered Recipient Entity
PMG RESEARCH INC
NN9924-4221 No dispute reported 06/30/2026 692464053
Principal investigator 1 Novo Nordisk AS $36,798.63 02/26/2019 Non-covered Recipient Entity
PMG RESEARCH INC
NN9536-4375 No dispute reported 06/30/2026 692464069
Principal investigator 1 Merck Sharp & Dohme Corporation $1,995.40 02/25/2019 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691317737
Principal investigator 1 Merck Sharp & Dohme Corporation $15,844.00 02/25/2019 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691320155
Principal investigator 1 PFIZER INC. $400.76 02/25/2019 Non-covered Recipient Entity
PMG Research of Wilmington LLC
A PHASE 3 RANDOMIZED OPENLABEL TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS 65 YEARS OF AGE WITH PRIOR PNEUMOCOCCAL VACCINATION No dispute reported 06/30/2026 671625355
Principal investigator 1 SANOFI US SERVICES INC. $8,349.00 02/25/2019 Non-covered Recipient Entity
Pmg Research,Incorporation
A Randomized, Double-blind, Placebo-controlled, 3-arm, Parallel-group 52-week Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin in Patients With Type 2 Diabetes Mellitus and Moder No dispute reported 06/30/2026 691611463
Principal investigator 1 Novo Nordisk AS $180.09 02/22/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4373 No dispute reported 06/30/2026 706703319
Principal investigator 1 Novo Nordisk AS $180.09 02/22/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4373 No dispute reported 06/30/2026 706703321
Principal investigator 1 Novo Nordisk AS $1,303.20 02/21/2019 Non-covered Recipient Entity
PMG RESEARCH INC
NN1250-4252 No dispute reported 06/30/2026 692464025
Principal investigator 1 Novo Nordisk AS $1,000.00 02/21/2019 Non-covered Recipient Entity
PMG RESEARCH INC
NN9924-4221 No dispute reported 06/30/2026 692464051
Principal investigator 1 Novo Nordisk AS $7,516.42 02/21/2019 Non-covered Recipient Entity
PMG RESEARCH INC
NN9536-4374 No dispute reported 06/30/2026 692464061
Principal investigator 1 Novo Nordisk AS $30,524.11 02/21/2019 Non-covered Recipient Entity
PMG RESEARCH INC
NN9536-4373 No dispute reported 06/30/2026 692464077
Principal investigator 1 PFIZER INC. $6,358.01 02/20/2019 Non-covered Recipient Entity
PMG RESEARCH INC
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671625963
Principal investigator 1 PFIZER INC. $9,380.45 02/20/2019 Non-covered Recipient Entity
PMG Research of Charlotte
PHASE III LOT CONSISTENCY TRIAL No dispute reported 06/30/2026 671628099
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $315.00 02/20/2019 Non-covered Recipient Entity
PMG RESEARCH INC
PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO AND NSAID CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP No dispute reported 06/30/2026 639750035
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $751.00 02/20/2019 Non-covered Recipient Entity
PMG RESEARCH INC
PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO AND NSAID CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP No dispute reported 06/30/2026 639750037
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $749.00 02/20/2019 Non-covered Recipient Entity
PMG RESEARCH INC
PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO AND NSAID CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP No dispute reported 06/30/2026 639750039
Principal investigator 1 SANOFI US SERVICES INC. $2,025.00 02/19/2019 Non-covered Recipient Entity
Pmg Research,Incorporation
A Randomized, Double-blind, Placebo-controlled, 3-arm, Parallel-group 52-week Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin in Patients With Type 2 Diabetes Mellitus and Moder No dispute reported 06/30/2026 691611453
Principal investigator 1 Merck Sharp & Dohme Corporation $3,872.00 02/13/2019 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691318279
Principal investigator 1 Merck Sharp & Dohme Corporation $1,797.00 02/13/2019 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691325981
Principal investigator 1 Merck Sharp & Dohme Corporation $124.75 02/13/2019 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691343961
Principal investigator 1 PFIZER INC. $4,309.21 02/13/2019 Non-covered Recipient Entity
PMG RESEARCH INC
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671624897
Principal investigator 1 PFIZER INC. $532.24 02/13/2019 Non-covered Recipient Entity
PMG RESEARCH INC
A PHASE 2 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF TWO 3DOSE REGIMENS OF A CLOSTRIDIUM DIFFICILE VACCINE IN HEALTHY ADULTS AGED 65 TO 85 YEARS No dispute reported 06/30/2026 671625895
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $87,028.64 02/13/2019 Non-covered Recipient Entity
PMG RESEARCH INC
PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO AND NSAID CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP No dispute reported 06/30/2026 639750033
Principal investigator 1 Novo Nordisk AS $117.78 02/12/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4375 No dispute reported 06/30/2026 706703285
Principal investigator 1 Novo Nordisk AS $1.70 02/11/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 706703295
Principal investigator 1 SANOFI US SERVICES INC. $675.00 02/11/2019 Non-covered Recipient Entity
Pmg Research,Incorporation
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin Added to Metformin in Patients With Type 2 Diabetes Mellitus Who No dispute reported 06/30/2026 691611325
Principal investigator 1 SANOFI US SERVICES INC. $16,039.00 02/11/2019 Non-covered Recipient Entity
Pmg Research,Incorporation
A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin in Patients With Type 2 Diabetes Who Have Inadequate Glyc No dispute reported 06/30/2026 691611335
Principal investigator 1 Novo Nordisk AS $307.97 02/07/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4375 No dispute reported 06/30/2026 706703293
Principal investigator 1 PFIZER INC. $16,394.47 02/06/2019 Non-covered Recipient Entity
PMG RESEARCH INC
A PHASE 2 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF TWO 3DOSE REGIMENS OF A CLOSTRIDIUM DIFFICILE VACCINE IN HEALTHY ADULTS AGED 65 TO 85 YEARS No dispute reported 06/30/2026 671624545
Principal investigator 1 PFIZER INC. $2,300.00 02/06/2019 Non-covered Recipient Entity
PMG RESEARCH INC
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671624965
Principal investigator 1 PFIZER INC. $200.38 02/06/2019 Non-covered Recipient Entity
PMG Research of Wilmington LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINENAIVE ADULTS 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671683397
Principal investigator 1 Novo Nordisk AS $1,000.00 02/05/2019 Non-covered Recipient Entity
PMG RESEARCH INC
NN9924-4223 No dispute reported 06/30/2026 692464049
Principal investigator 1 PFIZER INC. $21,215.87 02/05/2019 Non-covered Recipient Entity
PMG Research of Charlotte
PHASE III LOT CONSISTENCY TRIAL No dispute reported 06/30/2026 671628101
Principal investigator 1 PFIZER INC. $10,067.88 02/05/2019 Non-covered Recipient Entity
PMG Research of Wilmington LLC
A PHASE 12 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING FIRSTINHUMAN STUDY TO DESCRIBE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A RESPIRATORY SYNCYTIAL VIRUS RSV VACCINE IN HEALTHY ADULTS No dispute reported 06/30/2026 671632441
Principal investigator 1 PFIZER INC. $532.24 02/04/2019 Non-covered Recipient Entity
PMG RESEARCH INC
A PHASE 2 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF TWO 3DOSE REGIMENS OF A CLOSTRIDIUM DIFFICILE VACCINE IN HEALTHY ADULTS AGED 65 TO 85 YEARS No dispute reported 06/30/2026 671624751
Principal investigator 1 PFIZER INC. $6,104.67 02/04/2019 Non-covered Recipient Entity
PMG RESEARCH INC
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671625907
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,262.07 02/04/2019 Non-covered Recipient Entity
PMG RESEARCH INC
PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO AND NSAID CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP No dispute reported 06/30/2026 639750031
Principal investigator 1 Novo Nordisk AS $120.00 01/31/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4374 No dispute reported 06/30/2026 706703229
Principal investigator 1 SANOFI US SERVICES INC. $12,850.00 01/31/2019 Non-covered Recipient Entity
Pmg Research,Incorporation
A 26-week Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter, Phase 3 Study With a 78-week Extension Period to Evaluate the Efficacy and Bone Safety of Sotagliflozin in Patients No dispute reported 06/30/2026 691611320
Principal investigator 1 SANOFI US SERVICES INC. $9,406.50 01/30/2019 Non-covered Recipient Entity
Pmg Research Of Wilmington,LLC
A 56-week, Multicenter, Double-blind, Placebo-controlled, Randomized Study to Evaluate the Efficacy and Safety of Efpeglenatide Once Weekly in Patients with Type 2 Diabetes Mellitus Inadequately Contr No dispute reported 06/30/2026 691548061
Principal investigator 1 SANOFI US SERVICES INC. $845.00 01/29/2019 Non-covered Recipient Entity
Pmg Research,Incorporation
A 26-week Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter, Phase 3 Study With a 78-week Extension Period to Evaluate the Efficacy and Bone Safety of Sotagliflozin in Patients No dispute reported 06/30/2026 691611313
Principal investigator 1 Merck Sharp & Dohme Corporation $2,941.04 01/28/2019 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691391845
Principal investigator 1 Merck Sharp & Dohme Corporation $33,679.00 01/25/2019 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691310697
Principal investigator 1 PFIZER INC. $7,069.83 01/25/2019 Non-covered Recipient Entity
PMG Research of Charlotte
PHASE III LOT CONSISTENCY TRIAL No dispute reported 06/30/2026 671625395
Principal investigator 1 Novo Nordisk AS $38,999.14 01/24/2019 Non-covered Recipient Entity
PMG RESEARCH INC
NN1250-4252 No dispute reported 06/30/2026 692464023
Principal investigator 1 Novo Nordisk AS $5,752.14 01/24/2019 Non-covered Recipient Entity
PMG RESEARCH INC
NN9536-4374 No dispute reported 06/30/2026 692464055
Principal investigator 1 Novo Nordisk AS $16,756.43 01/24/2019 Non-covered Recipient Entity
PMG RESEARCH INC
NN9536-4374 No dispute reported 06/30/2026 692464057
Principal investigator 1 Novo Nordisk AS $50.00 01/24/2019 Non-covered Recipient Entity
PMG RESEARCH INC
NN9536-4374 No dispute reported 06/30/2026 692464059
Principal investigator 1 Novo Nordisk AS $49,302.37 01/24/2019 Non-covered Recipient Entity
PMG RESEARCH INC
NN9536-4375 No dispute reported 06/30/2026 692464067
Principal investigator 1 Novo Nordisk AS $650.00 01/24/2019 Non-covered Recipient Entity
PMG RESEARCH INC
NN9536-4373 No dispute reported 06/30/2026 692464073
Principal investigator 1 Novo Nordisk AS $72,065.83 01/24/2019 Non-covered Recipient Entity
PMG RESEARCH INC
NN9536-4373 No dispute reported 06/30/2026 692464075
Principal investigator 1 Novo Nordisk AS $675.57 01/24/2019 Non-covered Recipient Entity
PMG RESEARCH INC
EX9536-4388 No dispute reported 06/30/2026 692464081
Principal investigator 1 Novo Nordisk AS $698.24 01/24/2019 Non-covered Recipient Entity
PMG RESEARCH INC
EX9536-4388 No dispute reported 06/30/2026 692464083
Principal investigator 1 PFIZER INC. $24,064.25 01/23/2019 Non-covered Recipient Entity
PMG Research of Wilmington LLC
A PHASE 12 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING FIRSTINHUMAN STUDY TO DESCRIBE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A RESPIRATORY SYNCYTIAL VIRUS RSV VACCINE IN HEALTHY ADULTS No dispute reported 06/30/2026 671624837
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $315.00 01/23/2019 Non-covered Recipient Entity
PMG RESEARCH INC
PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO AND NSAID CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP No dispute reported 06/30/2026 639750027
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $37,157.83 01/23/2019 Non-covered Recipient Entity
PMG RESEARCH INC
PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO AND NSAID CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP No dispute reported 06/30/2026 639750029
Principal investigator 1 SANOFI US SERVICES INC. $10,572.00 01/22/2019 Non-covered Recipient Entity
Pmg Research,Incorporation
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin Added to Metformin in Patients With Type 2 Diabetes Mellitus Who No dispute reported 06/30/2026 691611189
Principal investigator 1 SANOFI US SERVICES INC. $675.00 01/22/2019 Non-covered Recipient Entity
Pmg Research,Incorporation
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin Added to Metformin in Patients With Type 2 Diabetes Mellitus Who No dispute reported 06/30/2026 691611211
Principal investigator 1 PFIZER INC. $50,278.47 01/16/2019 Non-covered Recipient Entity
PMG Research of Wilmington LLC
A PHASE 12 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING FIRSTINHUMAN STUDY TO DESCRIBE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A RESPIRATORY SYNCYTIAL VIRUS RSV VACCINE IN HEALTHY ADULTS No dispute reported 06/30/2026 671624349
Principal investigator 1 PFIZER INC. $6,348.36 01/16/2019 Non-covered Recipient Entity
PMG RESEARCH INC
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671624999
Principal investigator 1 Merck Sharp & Dohme Corporation $232.20 01/14/2019 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691347457
Principal investigator 1 SANOFI US SERVICES INC. $1,975.00 01/14/2019 Non-covered Recipient Entity
Pmg Research Inc
Six-month, Randomized, Open-label, Parallel-group Comparison of SAR341402 to NovoLog/NovoRapid in Adult Patients With Diabetes Also Using Insulin Glargine, With a 6-month Safety Extension Period No dispute reported 06/30/2026 691562327
Principal investigator 1 AstraZeneca UK Limited $5,031.60 01/11/2019 Non-covered Recipient Entity
Pmg Research Inc
A Long Term Outcomes Study to Assess STatin Residual Risk Reduction with EpaNova in HiGh Cardiovascular Risk PatienTs with Hypertriglyceridemia No dispute reported 06/30/2026 685000945
Principal investigator 1 AstraZeneca UK Limited $6,481.10 01/11/2019 Non-covered Recipient Entity
Pmg Research Of Charlotte Llc
A Long Term Outcomes Study to Assess STatin Residual Risk Reduction with EpaNova in HiGh Cardiovascular Risk PatienTs with Hypertriglyceridemia No dispute reported 06/30/2026 685000979
Principal investigator 1 AstraZeneca UK Limited $5,946.80 01/11/2019 Non-covered Recipient Entity
Pmg Research Of Hickory
A Long Term Outcomes Study to Assess STatin Residual Risk Reduction with EpaNova in HiGh Cardiovascular Risk PatienTs with Hypertriglyceridemia No dispute reported 06/30/2026 685001007
Principal investigator 1 AstraZeneca UK Limited $7,027.30 01/11/2019 Non-covered Recipient Entity
Pmg Research Of Raleigh
A Long Term Outcomes Study to Assess STatin Residual Risk Reduction with EpaNova in HiGh Cardiovascular Risk PatienTs with Hypertriglyceridemia No dispute reported 06/30/2026 685001037
Principal investigator 1 AstraZeneca UK Limited $4,494.80 01/11/2019 Non-covered Recipient Entity
Pmg Research Of Wilmington
A Long Term Outcomes Study to Assess STatin Residual Risk Reduction with EpaNova in HiGh Cardiovascular Risk PatienTs with Hypertriglyceridemia No dispute reported 06/30/2026 685001071
Principal investigator 1 Novo Nordisk AS $12.75 01/10/2019 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4374 No dispute reported 06/30/2026 706703179
Principal investigator 1 PFIZER INC. $4,100.00 01/09/2019 Non-covered Recipient Entity
PMG RESEARCH INC
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671624417
Principal investigator 1 PFIZER INC. $8,015.68 01/09/2019 Non-covered Recipient Entity
PMG Research of Charlotte
PHASE III LOT CONSISTENCY TRIAL No dispute reported 06/30/2026 671625851
Principal investigator 1 PFIZER INC. $4,565.70 01/09/2019 Non-covered Recipient Entity
PMG RESEARCH INC
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 671625955
Principal investigator 1 PFIZER INC. $13,505.58 01/09/2019 Non-covered Recipient Entity
PMG RESEARCH INC
A PHASE 12 RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY ADULTS 50 THROUGH 85 YEARS OF AGE No dispute reported 06/30/2026 671679791
Principal investigator 1 SANOFI US SERVICES INC. $700.00 01/09/2019 Non-covered Recipient Entity
Pmg Research Of Wilmington,LLC
A 56-week, Multicenter, Double-blind, Placebo-controlled, Randomized Study to Evaluate the Efficacy and Safety of Efpeglenatide Once Weekly in Patients with Type 2 Diabetes Mellitus Inadequately Contr No dispute reported 06/30/2026 691550561